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Course Portfolio for BIOS 412/812 Human Genetics: Synthetic Review Paper 
Abstract: This portfolio focuses on Human Genetics, an upper-division course taken 
primarily by biology majors to fulfill elective credit in their degree. This course studies 
the genetic basis for human variation, with the goal of placing this variation in the context 
of human evolutionary history and the consequences of this variation for medical 
understanding and treatments. In Human Genetics, students complete an original 
synthetic research paper on a human genetic disorder.  Through writing this paper, 
students are expected to learn how to navigate electronic databases and online resources 
on human genetic diseases, and to read and synthesize the primary scientific literature.  
This portfolio describes the teaching methods used to guide students through this process. 
The information and concepts to be taught in Human Genetics are expected to be useful 
for students going on to do research in a biological field, for those intending to pursue 
medical and health-related professions, and in general in producing informed and critical 
citizens who are empowered to make scientifically sound decisions. 
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1. Objectives of the Portfolio
The objective of this Peer Review Course Portfolio is to develop and document the 
curriculum for BIOS412/812, Human Genetics.  This course has been historically taught 
by a faculty member who is retiring, and so I took over this responsibility and taught the 
class for the first time in the Spring Semester of 2016.   
One goal of this portfolio was to make the learning objectives for this course explicit and 
design performance-based assessments.  Through the workshops and retreats in the Peer 
Review of Teaching Program, these goals were developed and ultimately incorporated as 
a list of specific learning objectives (included in the course syllabus) and just-in-time-
teaching (JiTT) weekly assignments.   
Because BIOS412 is an ACE10 class, it is expected provide the students with an 
educational experience that both teaches and assesses information collection, synthesis, 
interpretation, presentation, and reflection.  Thus, a second goal of this portfolio was to 
develop a research paper project that fulfills these goals. Documents provided to the 
students to guide their research and paper-writing and examples of student papers are 
included in the appendices. I used this portfolio to help me develop this new (to me) 
course, and will include it as documentation of teaching in my promotion and tenure 
packages.   
2. Description of the Course
Human Genetics focuses on advanced concepts in genetics, with an emphasis on human 
biology and applications of this knowledge to medical diagnosis and treatment.  This 
includes mechanisms of inheritance, the nature of genetic variation, how this variation is 
expressed, and how this variation exists in populations and over evolutionary time.  
General Genetics (BIOS-206) is a prerequisite for Human Genetics; it is therefore 
assumed that students will enter the class at least familiar with the molecular and cellular 
basis for biological inheritance, mechanisms and control of gene expression, the basic 
structure of the human genome, and the segregation of alleles in populations.   
Human Genetics is designated as an ACE10 course.  To fulfill the ACE10 learning 
outcome ("generate a creative or scholarly product that requires broad knowledge, 
appropriate technical proficiency, information collection, synthesis, interpretation, 
presentation, and reflection") students write a synthetic review paper on a human genetic 
disease over the course of the semester.   
The major learning objectives in Human Genetics include (see Appendix A for syllabus): 
1) understand the current, state-of-the-art methods used to identify genetic variation
in humans and the approaches used to connect genetic variation to phenotypic
variation, particularly disease phenotypes;
2) understand how human genetic variation informs our understanding of disease
and guides and constrains health care decisions
3) develop the critical skills required to comprehend, interpret, and critique the
primary scientific literature, with the ultimate goal of empowering students to
independently approach the scientific literature
4) synthesize a body of primary scientific literature on a human genetic disease and
write a review of the disease, describing its genetic underpinnings, its phenotypic
outcomes, and current and future approaches for diagnosis and treatment.
Student learning of these course goals was assessed using weekly short answer problem 
sets based around the textbook or assigned reading; three midterm exams; and a research 
paper synthesizing the scientific literature on a human genetic disorder. 
In the spring semester of 2016, Human Genetics had an enrollment of 22 students in the 
undergraduate section (BIOS-412) and one student in the graduate section (BIOS-812).  
Of the 22 students enrolled in BIOS-412, 15 were seniors, five were juniors, and two 
were graduate students.  Majors included biological sciences (15 students), psychology 
(1), forestry (1), microbiology (1), biochemistry (1) and plant biology (1).   
3. Teaching methods
Classroom instruction and assignments: The primary mode of in-class instruction in 
Human Genetics was canonical lecture.  I utilized both the white-board and projected 
presentations - concepts and details were loosely transcribed from prepared notes on to 
the white board, while the presentation slides were mainly used to provide the students 
with figures and tables from the textbook or primary literature.  I wrote on the board, 
rather than presenting the students with pre-written text on slides, to slow down my 
presentation of the material and provide students time to take their own notes and 
assimilate the material. 
At least once during most classes I presented the students with a multiple-choice question 
and solicited student answers via clickers.  If a majority of the answers were incorrect, 
the students were given the opportunity to discuss the question amongst themselves and 
then I posed the question again.  In almost every case the class converged on the correct 
answer.  After presenting the correct answer, I asked students to explain what exactly was 
wrong with the incorrect answers. Often the question was posed at the very beginning of 
class, as a way of focusing the students' attention and setting the atmosphere for the rest 
of the class period. 
Outside of class, the students were expected to read the textbook (Genetics and Genomics 
in Medicine, Strachan et al. 2015) and papers from the primary scientific literature.  They 
were also required to complete short weekly assignments through Blackboard based on 
the assigned reading.  These assignments consisted of 3-5 short-answer questions, and 
were assigned at the end of the week and due Monday at 11:00 (24 hours prior to class on 
Tuesday). The assignments were then graded before class on Tuesday and the students' 
answers were used to guide both the lecture topics and in-class questions (Just-in-Time-
Teaching).  Frequently the in-class question would repeat or re-state the assigned 
question that seemed to provide the students with the most difficulty.  Students were 
given full credit on the assignments for simply providing a reasonable answer, but I 
awarded more points (that did not go towards their final grades) for correct answers.  
These points allowed the students to see whether their answers were correct and helped 
guide their studying for the midterm exams, since some assigned questions were repeated 
verbatim or only slightly modified on the exams. 
Human Disease Review Paper: The major assignment outside of class was the review 
paper, which constituted 20% of the final grade for the semester.  The project was carried 
out in stages throughout the semester, with each stage requiring an assignment to be 
turned in that contributed to part of the 20% of the grade associated with the whole 
project.  At most stages the students got full credit for simply completing that part of the 
assignment on time; but the rough draft and final draft of the paper were graded on the 
merits of the work.  The rationale for dividing the assignment into stages was 1) to spread 
the workload out over the semester and prevent students from procrastinating; 2) allow 
me to provide feedback, guidance, and course corrections throughout the process.  The 
stages of the research paper assignment are described below: 
Stage 1. Students were first introduced to the disease project with a document (Appendix 
B.1) and an in-class presentation on the internet resources available for researching these 
diseases.  The presentation focused on two databases hosted by the National Institutes of 
Health (NIH): Online Mendelian Inheritance in Man (OMIM) and the Genetics Home 
Reference.  These databases provide extensive information regarding human genetic 
diseases. OMIM is more technical and extensively references the scientific literature; it is 
equivalent to hundreds of review articles in a database format.  The Genetics Home 
Reference site is more user friendly, presents information that is more accessible to the 
layman, and provides information on disease advocacy and support organizations.  The 
presentation also introduced the class to websites and search engines for investigating the 
scientific literature, especially Google Scholar and Pubmed (hosted by NIH).  I also 
encouraged the judicious use of Wikipedia, as a repository of basic and non-controversial 
information (although it may not always be apparent what entries on Wikipedia belong to 
this category). Finally, students were given a list of 15 human genetic diseases and 
encouraged to briefly research the diseases on the list, choose one that would be their 
focus of their paper, and write a brief summary of their chosen disease's characteristics. 
With my permission, two students chose diseases not originally on the list; these 
additions will be incorporated in the next iteration of the class. Students were required to 
convey their choice as one of the assigned homework questions due the second Tuesday 
class of the semester.
Stage 2. The second stage of the project required the students to find a peer-reviewed 
primary research paper (not a review) from the literature on their chosen disease and 
provide a summary of this paper. The structure of this summary was provided to the 
students in the document included in Appendix B.2. These assignments allowed me to 
ensure that the students were discovering appropriate scientific literature and provided 
them with a framework for critically reading the scientific literature, and for restating the 
often technical language in journal articles in their own words. These assignments were 
due the third (choosing an article) and fourth (summarizing the article) Tuesday classes 
of the semester. 
Stage 3. The third stage in the project was a list of 10 references on the students' chosen 
disease topic that would form the basis for their research.  This assignment allowed me to 
ensure that students were accessing recent, relevant, peer-reviewed scientific literature for 
use in their research.  This assignment was due in the sixth Tuesday class of the semester. 
Stage 4. The next stage of the project was an outline of the paper, following the structure 
provided in Appendix B.3 as a guide.  This document provided the students with a 
description of the major sections their paper could contain, and specific questions their 
research should answer.  The outline was due Thursday of the eighth week of the 
semester.   
Stage 5. The fifth stage was a draft of the final paper.  The draft was to be complete, with 
proper formatting, citations, and polished spelling and grammar.  These drafts were 
carefully graded and commented to provide the students with the necessary feedback to 
write a high-quality final draft, and if all the comments were addressed, the final draft 
received a high grade.  The drafts were due on Thursday the 14th week of the semester.   
Stage 6. The final stage in the project was the completed research paper, due the Tuesday 
of finals week.   
4. Analysis of student learning
Gender effects on student performance: Student grades were comprised of homework 
assignments, the stages of the research paper, and three in-class exams; the majority of 
class points were assigned to the exams (60%).  Exams consisted of a mix of multiple 
true/false, short answer, and problem-solving questions.   
Unexpectedly, a stark and statistically significant effect of gender was observed on the 
distribution of class grades (Figure 1).  This effect was most pronounced for the three 
exams, as the grade distribution was the widest (greatest variance) for this component of 
the class, but was also observed to a lesser extent in the distribution of final grades that 
included homework assignments and the research paper.  In all cases, the nine female 
students significantly outperformed their 14 male counterparts. This effect was strongest 
for exam #1, where the median female student score was 92, while the median male 
student score was 78.5 (P-value = 0.001).  On each exam, the top three, two, and five 
scores all belonged to female students (exams 1,2, and 3 respectively); and the top five 
final grade scores were all given to female students.   
Figure 1. (A) Boxplots of grades for three in-class Exams and the Final Grade 
(%) for the semester, separated by student gender. Female student 
distributions are indicated in red; male students in blue.  Outlier points are 
indicated as circles.  P-values from a Mann-Whitney test of the difference 
between median exam scores for female and male students are indicated 
above the boxplots.  The grades for Exams 1 and 2 were scaled by adding four 
and eight points to each score, respectively, which resulted in some (female) 
students earning > 100 points for the exam.  One female student who stopped 
attending the class was excluded from the plot for Exam 3 and the Final 
Grade, as she did not take the exam or finish the final project. (B) Distribution 
of final letter grades separated by gender. 
As there is currently only data from one year of this course, it remains to be seen whether 
this result reflects a general trend among students choosing to enroll in Human Genetics, 
or whether this was merely a one-time effect. 
Human Disease Review Paper: At all stages of the review paper project, feedback was 
provided to the students.  
Most students correctly identified relevant primary literature sources for their first paper 
(Stage 2).  The most common error at this stage was choosing a review paper that did not 
present new data or experiments (four students initially chose review papers). This error 
was unsurprising, since the distinction between review articles and articles that present 
new results is most likely unknown to students who have not had extensive experience 
with the scientific literature, and not always easy to discern (although three of the chosen 
review articles did explicitly state that they were review articles in the abstract).  Other 
inappropriate choices included a study that focused very narrowly on a treatment of one 
specific manifestation of the disease, rather than the underlying genetic basis or more 
general therapeutic or surgical treatments.  Students were provided with this corrective 
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feedback over email, and all students selected appropriate papers for their summaries on 
the second try. 
Student summaries of the first paper were largely acceptable, suggesting that the template 
provided in Appendix B.2 provided them with enough structure to allow them to dissect 
the primary literature.   
Student lists of 10 relevant peer-reviewed publications (Stage 3) were also all acceptable, 
suggesting that the instruction provided in Stage 1 and the feedback on the first paper 
choices sufficiently enabled the students to navigate the scientific literature. 
Outlines of the research paper (Stage 4) were assigned mainly to encourage the students 
to make substantial progress on their research well in advance of the deadline for 
completing the final product, and thus students were given full credit for completing the 
assignment on time, and minimal feedback was provided on the structure or content of the 
outline. Outlines ranged from minimal (Appendix C.1) to virtually completed final papers 
(Appendix C.2).   
The first drafts of the research papers, predictably, showed a wide range of quality, from 
polished, completed papers that required minimal revision before submitting the final 
version, to drafts that were incomplete, poorly structured, and replete with grammatical 
errors.  By far the most common errors involved the use of citations, particularly their 
formatting.  Many students used a numbered citation format, but failed to order the 
citations by their appearance in their paper.  Other students used an (author, year) citation 
format but failed to include the year in the in-text citation.  Some students repeatedly 
cited the same source in multiple consecutive sentences, rather than including a single 
citation at the end of the section.  Multiple students failed to adequately cite the literature 
throughout their paper; two students did not include any in-text citations at all, and one 
student failed to provide a bibliography of their references.  These errors were 
unsurprising, given that most of these students likely had little or no experience with the 
citation style in scientific publications, and all errors of this kind were readily corrected 
for the final version of the paper. 
Nine examples of both the first and final draft papers are provided in the appendix.  
Comments and suggestions for improvement were provided on hard copies of the first 
drafts and returned to the students. The first three examples (Appendix D.1, Appendix 
D.2, and Appendix D.3) represent the best submissions - cases where the first draft was 
virtually complete and required minimal edits for the final draft and students received 
perfect grades on both drafts.
The next three examples (Appendix D.4, Appendix D.5, and Appendix D.6) represent 
average student submissions.  These first drafts all required significant modification 
before the final version and were all scored at 70%.  In addition to formatting and 
grammatical errors, the first drafts in this group required extension and elaboration of one 
or more sections of the paper. These three students varied in the success with which they 
improved their paper for the final version, earning a 95%, 97%, and 92% on the final 
draft (Students 4, 5 & 6 respectively). 
The final three examples (Appendix D.7, Appendix D.8, and Appendix D.9) represent 
low-quality student papers.  The first drafts were scored at 60% (Students 7 & 8) and 
80% (Student 9).  The first drafts from students 7 & 8 were all incomplete in some way 
and required extensive modification.  The first draft from student 9 was largely complete 
and required only minor edits and some changes to formatting and citations, but many of 
these changes were not incorporated in the final version, leading to only a mild 
improvement in score for the final draft (90%).  Both students 7 & 8 did improve their 
papers for the final version, scoring a 83% and 87% respectively, but these final papers 
were still of poorer quality than the average paper in the class. 
5. Planned Changes
I felt that the mix of projected slides and writing on the board worked well and allowed 
the students time to take careful notes, while also enabling me to use relevant figures and 
tables from the textbook or the literature to illustrate relevant concepts.  The exam 
structure also succeeded in identifying what concepts the students did and did not learn.  
On each of the first two exams, the students did very poorly on one question (overall 
scoring 33% and 22% of the total possible points); the points corresponding to these 
questions were then added back each student's exam.  In future classes, I will either make 
an extra effort to convey the concepts assessed by these questions, or rewrite the exam 
questions to try and better match what was taught. 
In future iterations of this class, I intend to increase the time spent both in and outside of 
class on reading and interpreting the scientific literature.  The assigned readings and in-
class discussion of the papers clearly engaged the students and conveyed to them both 
scientific knowledge but also how that knowledge is obtained - something that is not as 
readily apparent in textbooks.  Ideally, the class would have no textbook but would rely 
solely on primary scientific literature, review articles, and some science writing for the 
lay public; but it may be a few more iterations before that becomes possible. 
Many aspects of the review paper project went well.  In the future I intend to incorporate 
two changes to this project.  First, the students needed more practice restating complex 
and technical scientific language in their own words.  This was clearly a challenge for 
most of the students; a few approached this problem by extensively quoting the articles 
they read in their paper, which, although ethically defensible, neither encourages 
synthesis of the information nor makes for very readable text. This will be a significant 
challenge, given how extremely technical and detailed the relevant literature is; but 
nonetheless worth attempting. I think doing this together as a class for one paper, before 
each student summarizes a paper on their chosen disease topic, would be the simplest 
way to provide the class with this practice.  Second, I intend to provide more detailed 
feedback at the outline stage of the project.  I would like to give the students freedom to 
focus on the aspects of their research topic that interest them the most, and would like to 
avoid constraining them too much with prescribed templates and formats; there is already 
plenty of that in Appendix B.3.  This motivated using the outline solely as a guard 
against procrastination, and not critiquing the content of student outlines.  However, I 
think this is outweighed by the benefits of being able to provide students with feedback 
regarding which aspects of their papers could be more or less detailed, and encouraging 
them to find more or different source articles early in the writing process.  Requiring both 
a 
"draft" and final version of the outline could also allow me to set a higher bar for the final 
draft of the outline, aspiring for all students to produce a document on par with the best 
outlines submitted this semester (Appendix C.2). 
6. Summary and Synthesis
The first iteration of the human disease review paper, although not without flaws, seemed 
to be largely a success.  Even the lowest-scored review papers were substantial works of 
research, and students clearly learned many concepts and details regarding their chosen 
disease.  Informal student feedback indicated that students enjoyed the project, and found 
the staged structure helpful in guiding their research and writing and preventing 
procrastination, as was intended.  Although it may be modified, I intend to include this 
project in future iterations of the class. 
The Peer Review of Teaching Project was unquestionably useful in helping me to 
develop Human Genetics and design the human disease project.  But I feel its benefits go 
beyond this specific course. By facilitating discussion of pedagogy and encouraging 
instructors to approach teaching as if it were research (designing experiments and 
collecting data on student learning), this project helped me to think more critically and 
carefully about my teaching; about what my expectations of student learning are and how 
to match my teaching to help students meet those goals; and empowered me to actively 
and effectively work to improve my teaching.   
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A. Course syllabus for Human Genetics, Spring Semester 2016
B. Teaching materials for the human genetic disease research project
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C. Sample student outlines for the genetic disease research paper
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D.1. Student #1 rough/final drafts ("Celiac Disease Review")
D.2. Student #2 rough/final drafts ("Hutchinson-Gilford Progeria Syndrome")
D.3. Student #3 rough/final drafts ("Lesch-Nyhan Disease")
Examples of middle-achievement papers 
D.4. Student #4 rough/final drafts ("Marfan Syndrome")
D.5. Student #5 rough/final drafts ("Primary Ciliary Dyskinesia")
D.6. Student #6 rough/final drafts ("Parkinson's Disease ")
Examples of low-achievement papers 
D.7. Student #7 rough/final drafts ("Werner Syndrome")
D.8. Student #8 rough/final drafts ("Sickle Cell Disease")
D.9. Student #9 rough/final drafts ("Analyzing the Genetic and Clinical Aspects
of the Mutation in the Cystic Fibrosis Transmembrane Regulator Gene ")
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BIOS 412/812: Human Genetics 
 Spring 2016 syllabus 
Class meets Tuesday and Thursday 11:00-12:15 PM, Beadle Center 176 
Instructor:  Dr. Colin Meiklejohn, Assistant Professor, School of Biological Sciences 
Office: 302A Manter Hall 
Office hours: scheduled by appointment 
email: cmeiklejohn2@unl.edu 
Textbook:  Genetics and Genomics in Medicine. Strachan, Goodship and Chinnery 
(the digital version is a cheaper option) 
Clickers are required 
Course description and learning objectives:  This course focuses on advanced concepts 
in genetics, with a focus on human biology and applications of this knowledge to medical 
diagnosis and treatment.  This includes mechanisms of inheritance, the nature of genetic 
variation, how this variation is expressed, and how this variation exists in populations and 
over evolutionary time.  In fulfillment of the ACE10 learning outcome ("generate a 
creative or scholarly product that requires broad knowledge, appropriate technical 
proficiency, information collection, synthesis, interpretation, presentation, and 
reflection") you will write a synthetic review paper on a human genetic disease.  Through 
this project you will learn to search scientific literature; how to read and interpret the 
scientific literature; and how to write a short review of recent scientific publications on 
the disease. 
Expectations:   
BIOS206 (General Genetics) is a prerequisite for Human Genetics.  I therefore assume 
that students are familiar with the molecular and cellular basis for biological inheritance, 
mechanisms and control of gene expression, the basic structure of the human genome, 
and the segregation of alleles in populations.   
For each lecture topic, you will have assigned reading and questions about the reading.  
The questions will be posted on Blackboard and are due by noon the day before class.  
These assignments are due the day before class so that we can spend class time focused 
on the concepts that are challenging to the most students; I need the time to adjust the 
next day's lecture based on your answers.  Completing these assignments is part of your 
grade; but you will get full credit so long as you make an honest effort to answer the 
questions to the best of your ability.  
I expect that you will come to class, read the textbook and assigned papers from the 
scientific literature, do the assigned homework problems, think, have fun and use logic 
over memorization.  Please take advantage of office hours if you are struggling with the 
material, sooner rather than later. 
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Learning in groups is encouraged, but this is only effective if all group members are 
contributing. The reading assignments may be done together with other students, but if 
someone else is doing most of the work, you will likely get poor exam grades.  Copying 
someone else’s homework and turning it in as your own work is not only a violation of 
the Student Code of Conduct (for both students), it is an ineffective way of learning the 
material and preparing for the exams. 
Evaluation and grading:  Your course grade is based on three midterm exams, 
homework assignments and a synthetic review paper investigating a human genetic 
disease.  Each of these 5 components (3 midterms, homework, research paper) comprises 
20% of the final grade.  Depending on the results, midterm exam scores may be scaled.  
Final grades will be determined as follows (out of 500 points): 
495 (99%)  A+ 440 (88%)  B+ 390 (78%)  C+ 340 (68%)  D+ 
460 (92%)  A  410 (82%)  B 360 (72%)  C  310 (62%)  D 
450 (90%)  A-  400 (80%)  B- 350 (70%)  C-  300 (60%)  D- 
         
 
Academic integrity:  Students are expected to adhere to guidelines concerning academic 
dishonesty outlined in Section 4.2 of University’s Student Code of Conduct. Violations of 
this policy will result in a minimum sanction of a grade of zero being given for the 
graded item on which the violation occurred, and may include other actions, such as an F 
for the course. All incidents will be reported to the Dean of Students. Behavior and 
remarks that disparage persons or activities in the course, or detract from a serious 
learning environment are not tolerated. 
Email policy: Students are encouraged to contact the professor via email; however, 
please be respectful in your use of email.  Many details about the course can be found in 
this syllabus, and conceptual questions are better discussed in lecture, office hours, and 
study sessions.  Please do not fill the instructors' inboxes with every question that may 
arise regarding course material.  Email is a good way to schedule appointments and 
conduct course-related business. When you do email, it should be considered a formal 
means of communication, and messages must be structured accordingly.  This means that 
each email must include an informative subject header, an appropriate salutation, 
complete sentences with accurate spelling and punctuation, and an appropriate closing 
and signature.  Emojis are acceptable.  Emails that do not follow this structure may or 
may not be answered.  These rules will help prepare you for virtually any future 
employment, as email is a ubiquitous form of professional communication.   
Students are strongly encouraged to send email through Blackboard or from @huskers or 
@unl email address.  In the past I have experienced problems receiving email from 
services such as yahoo and rocketmail, and so messages sent from these accounts may 
not be answered. 
Students with Disabilities: Students with disabilities are encouraged to contact me, or a 
teaching assistant, for a confidential discussion of their individual needs for academic 
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accommodation. It is the policy of the University of Nebraska-Lincoln to provide flexible 
and individualized accommodations to students with documented disabilities that may 
affect their ability to participate fully in course activities or to meet course requirements. 
To receive accommodation services, students must be registered with the Services for  
 Students with Disabilities (SSD) office, 132 Canfield Administration, 472-3787. 
Learning Goals Strachan et al 
reading 
Background material 
• Explain the relationship between nucleotides, DNA, genes,
chromatin, nucleosomes, chromosomes
• Describe DNA replication and transcription
• Describe the processes of genome replication and cell division
• Compare and contrast mitosis and meiosis
• Explain homolog pairing and recombination in meiosis
• Describe the difference between introns and exons and explain
splicing
• Explain the genetic code and the role of RNA molecules in gene
regulation, including transcription and translation.
• Describe the structure of the human genome, explain gene families
and repetitive DNA
Chapters 1 & 2 
• Explain and diagram DNA cloning, PCR, and DNA sequencing
• Explain the principles and uses of nucleic acid hybridization
Chapter 3 
• Explain the process of mutation and the generation of genetic
variation
• Describe the structure of genetic variation in human populations
• Explain the signatures and consequences of natural selection acting in
human populations
Chapter 4 
• Perform genetic inference based on segregation of genotypes and
phenotypes in families and populations
• Calculate genotype frequencies from allele frequencies under Hardy-
Weinberg equilibrium
Chapter 5 
• List the classes of cis-regulatory sequences, trans-regulatory proteins,
and small regulatory RNAs and how they  regulate gene expression
(both transcriptional and post-transcriptional regulation)
• Explain how chromatin modification regulates gene expression
• Describe the role of epigenetics in human diseases
Chapter 6 
• Describe how genetic variation results in disease
• Describe the role of repetitive DNA in disease
• Predict transmission patterns of chromosomal abnormalities
Chapter 7 
• Describe genetic studies used to understand disease inheritance Chapter 8 
• Describe genetic treatments and genetic interactions with drug
treatments
Chapter 9 
• Describe the genetics and progression of cancer
• Explain the advances derived from genomic studies of cancer
Chapter 10 
• Compare and contrast technical and ethical aspects of genetic testing Chapter 11
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Course Calendar 
January 19 Identify human disease topic 
January 26 Identify recent scientific publication on chosen disease 
February 11 Synopsis of recent publication due 
February 11 Exam I 
February 25 List of citable publications 
March 15 Review outline  
March 17 Exam II 
April 5  Review rough draft 
April 28 Exam III 
May 3 Review paper 
Human genetic disease project Appendix B.1 
This semester you will write a synthetic review paper on a human genetic disease.  
Through this project you will learn to search scientific literature; how to read and 
interpret the scientific literature; and how to write a short review of recent scientific 
publications on the disease. 
The first step is to choose from one of the human genetic disorders listed below.  These 
disorders vary in their severity, quality of life, genetic basis, and currently available 
treatments. You can learn about each of these conditions from many online sources, 
which you will also use to find scientific articles about the condition you choose to 
research:  
Google (search, news, scholar) 
Wikipedia 
*Genetics Home Reference (http://ghr.nlm.nih.gov/)
*Online Mendelian Inheritance in Man (OMIM - omim.org)
Web of Science: used to find primary (journal) articles and review articles in biology and
other scientific disciplines
PubMed: provides access to Medline, used to find primary (journal) articles and review
articles in the biomedical sciences
EurekAlert!: features science, health and technology news; sponsored by the American
Association for the Advancement of Science (http://www.eurekalert.org/)
Science Daily: breaking science news stories and feature articles
(http://www.sciencedaily.com/)
Human disease topics  
Angelman syndrome 
Beckwith-Wiedemann syndrome 
Beta thalassemia 
Celiac disease  
Cystic fibrosis 
Duchenne and Becker muscular dystrophy 
Hutchison-Gilford syndrome 
Leigh syndrome 
Lesch-Nyhan syndrome 
Marfan syndrome 
Parkinson disease 
Prader-Willi syndrome 
Sickle cell disease 
Tay-Sachs disease 
Werner syndrome 
Human genetic disease project Appendix B.2 
This assignment is worth 2% of your course grade, and is due at the beginning of 
class on Tuesday, February 9.  
The second step in this project is to write a summary of the primary literature article you 
have selected on a human disease. The goal of this exercise is to help familiarize you 
with the structure of a scientific paper and how to extract information from them.  The 
following sections of your synopsis correspond to the sections of a typical scientific 
article, although not all articles will indicate each section with an explicit header.  For 
each section, write a few sentences or a short paragraph addressing the prompts listed 
below.  Given the technical nature of these articles, describing the methods and results in 
your own words may be significantly challenging; however this challenge is precisely the 
purpose of this assignment.  Copying a sentence verbatim from the article is not 
acceptable. 
Abstract 
Write 1-2 sentences that re-state, in your own words, a result highlighted in the paper's 
abstract. 
Introduction 
What aspect of the disease (genetic basis, phenotypic manifestation, treatment options) is 
addressed in this paper?   
Methods 
Summarize one of the main experiments in the paper as follows: 
- Describe the authors' hypothesis or hypotheses
- Describe at least one experiment that they do to test their hypotheses
- What is the logic behind this experiment?
Results 
What type of data did the authors collect? 
What is the main result to come out of this experiment? 
What conclusions do the authors draw from their results? 
Future directions 
What are the implications of this work for this particular disease?  How will the research 
(eventually) lead to improved quality of life for individuals with this disease? 
Describe one experiment that could be done as a follow-up to the experiments described 
in the paper. 
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Human Genetic Disease Research Project 
 
The following outline provides a recommended structure for your disease research 
paper.  Your paper should include most or all of these points, assuming that they are 
applicable to your chosen disease.  These recommendations may also help you identify 
interesting primary literature articles that directly address one or more of these topics.   
 
Provide an introduction to the disease 
• Give a brief summary of the disease, including but not limited to: what defines the 
syndrome, phenotypic range, physiological effects, prognosis, and quality of life. 
• What is the epidemiology of the disease? Or, how often does the disease occur, in 
which populations, how many births? Discuss details about higher incidence in 
certain cultures, geographical areas, or other boundaries.  
• What is the inheritance pattern? (autosomal, sex-linked, dominant, recessive, etc.) 
Does this have a relation with the epidemiology? 
• Provide a brief historical perspective of the disease. Who discovered it and when? 
Who now supports research of it? Is the disease in the news? What advocacy groups 
exist for the disease?  
 
Define the genetic component of the disease 
• What gene(s) underlie this disease, and how was the genetic component discovered? 
• What would the karyotype of an affected individual look like (if different from normal)? 
• What is the wild-type role of the gene? 
• What are the most commonly reported mutations? 
• What are the population genetics of the disease alleles?  How frequent are disease 
alleles, and are there differences in frequencies between populations?  What 
selective pressures are hypothesized to act on genotypes with one or two copies of 
the disease allele(s)? 
 
Describe the molecular biology and biochemistry of the disease 
• What is the phenotype of the disease at the cellular level?  What cells or tissues are 
involved? 
• Does the gene(s) encode a protein?  What does the protein do?  Is the protein 
involved in a known pathway? 
• How does the mutant form of the gene affect the cell? 
• Find the homolog of the protein in rhesus monkey, mice, and Drosophila.  Is the 
mutation in a conserved region? 
 
Clinical aspects and organismal phenotypes 
• Diagnostic tests 
• Variability in phenotype: penetrance and expressivity 
• Role of the genetic element in other diseases 
• Animal models 
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Issues for the affected individual and treatments/prospects 
• What are the major challenges faced by individuals with the disease? 
• What is the current state-of-the-art in detection, treatment, or avoidance (e.g. 
screening pre-implantation embryos)? 
• What are some potential treatments that have been proposed or are in research and 
development (e.g. clinical trials)? 
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BIOS 412: Human Genetics 
Celiac Disease Review Final Draft  
 Celiac disease belongs to the class of autoimmune disorders in which an immune 
response is mediated upon the body’s own healthy tissues, causing tissue damage and 
inflammation. The genomic region that has been associated with several autoimmune diseases is 
the human leukocyte antigen (HLA) or major histocompatibility (MHC) region on chromosome 
6. Upon the ingestion of foods containing the gluten protein, patients with celiac disease trigger 
an immune response that results in a range of enteropathies that are most commonly 
characterized by mucosal damage and villous destruction. Traditionally, a gluten-free diet has 
been the most effective treatment, but emerging research has presented innovative treatments 
that work at the molecular level, by binding and blocking the binding site of the antigen-
presenting molecule HLA-DQ2 and/or HLA-DQ8 [1].  
 The immune system is extremely polymorphic; its genetic variation has been under 
positive selection in order to maximize the number and types of proteins (MHC proteins and 
others) that bind specific foreign molecules that might be pathogenic. As a result, fully 
understanding the exact genetic components that contribute to an autoimmune disease is often 
quite challenging. To further establish the complexity of an autoimmune disease, it is worth 
mentioning that genes within the HLA region are packed into a small region amounting to only 
about 2% of chromosome 6. And, as a result, a haplotype of this nature (where genes are within 
close proximity to one another) tends to be clustered in genes that are inherited together as the 
chance of the genes being separated by recombination is low [2].  
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There are several major challenges celiac disease patients have to manage besides 
adhering to a strict gluten-free diet. Celiac disease is associated with numerous other enteric 
malignancies and autoimmune diseases that can afflict multiple body organs and systems 
including endocrine, hepatic tissue, and the nervous system. The most common associated 
disease is dermatitis herpetiformis, characterized by the formation of itchy skin lesions and 
erythematous papules. Individuals affected with this disorder are also likely to carry HLA-
DQ2/DQ8 alleles. Overall, patients can expect to endure more complications than those resulting 
directly from celiac disease, such as diarrhea and abdominal pain [3].  
 The oldest historical records describing celiac disease come from the Greek physician 
Aretaeus of Cappadocia between the 1st and 2nd centuries AD. The symptoms were reported, but 
the exact cause was not. It was not until the 19th century that British physician Samuel Gee 
would propose the idea that celiac disease is linked to diet, which was later confirmed in the 
1950’s by Dicke and colleagues who established that foods containing gluten, including wheat, 
barley, and rye, are the cause of symptoms [4]. 
 Current consensus indicates that the worldwide prevalence of celiac disease is at about 
1% of the general population, with higher incidences among females. However, some regions 
show increased prevalence, such as Western Sahara, while other countries like Burkina Foso 
have had no reported cases [1]. Celiac disease is a polygenic disorder that follows a complex, 
non-Mendelian inheritance pattern that is centered about the HLA region in which certain alleles 
associated with the disease show strong linkage disequilibrium, or nonrandom association [5]. In 
addition, recent findings confirmed the differential expression of certain genes in children 
patients as opposed to adult patients, suggesting an age effect [6]. 
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 There are several key molecular interactions that underlie the symptoms of celiac disease. 
The pivotal molecules are HLA-DQ2 and/or HLA-DQ8 antigens and T-cells, which interact 
directly to generate the destructive autoimmune response. HLA-DQ2/HLA-DQ8 heterodimers 
that are specific for gluten binding use a T cell repertoire (TCR) that binds gluten-derived 
peptide antigens and present them to T-cells which then secrete inflammatory cytokines in 
response. The unusual molecular structure of gluten proteins, which are nearly half composed of 
proline and glutamine residues, which makes them more difficult to digest in the intestinal tract, 
ultimately resulting in the formation of many small peptide fragments that are susceptible to 
chemical modification by tissue transglutaminase and subsequent HLA-DQ binding [7].  
 There are many candidate genes at multiple loci in several chromosomes in HLA and 
non-HLA regions that are suspected of contributing to the genetic risk of pathogenesis [1]. The 
allele that shows the strongest association with celiac disease is HLA-DQ2 [8]. Furthermore, a 
dosage effect has been observed. Children who inherit a copy of HLA-BQB1*02 (one of the 
alleles that encode for HLA-DQ2) from both parents were found to be at a higher risk of 
developing celiac disease than those who inherited the allele from only one parent [1].  
 It is important to note that the vast majority of people who carry the HLA-DQ2 or HLA-
DQ8 predisposing alleles will not manifest celiac disease. It is only the majority of those who are 
already affected with celiac disease that have been found to carry the HLA-DQ2/DQ8 allele. 
This is a good indicator of other non-MHC allele factors contributing to pathogenesis, such as 
epigenetics and the environment (diet). Surprisingly, recent evidence uncovered by genome-wide 
association studies (GWAS) suggest that the vast majority of SNP’s that are associated with 
disease occur in non-coding regions of the genome, including regulatory sequences (promoters, 
enhancers, etc…) and non-coding RNA (ncRNA) genes [1]. A special class of noncoding 
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RNA’s, microRNA, was found to be differentially upregulated as revealed by biopsies of celiac 
disease patients and controls. Specifically, a miRNA known as miR-449 was found to be the 
most upregulated. That miRNA also happens to be the one that targets mRNA’s that code for the 
translation of the NOTCH1 inflammation regulator. In concordance with the finding, NOTCH1 
was discovered to be at lower concentrations in the small intestines of patients with celiac 
disease. Overall, however, not much data have yet been gathered in support of the role of 
ncRNA’s in celiac disease [9].  
 Another epigenetic mechanism suspected to contribute to increased risk of celiac disease 
is allele specific methylation, which also occurs in noncoding sequences. Using microarray 
screening technologies, Hutchinson and others reported finding allele-specific methylation at 
several expression quantitative trait loci, one of which was the long non-coding RNA DLEU1 
that has been associated with celiac disease [10].  
 In order to obtain a good understanding of the disease and its mechanism, the focus of 
discussion will shift to the actual site of action: epithelial cells of the small intestines. To start 
off, the CD4 T cells that are specific for gluten peptides bound to HLA-DQ2/DQ8 have only 
been detected in celiac disease patients [11]. Upon examination, T-cell receptor usage was found 
to be biased among patients as opposed to controls, and a key non-germline encoded arginine 
residue was discovered as part of the T-cell receptor structure and determined to be essential in 
the binding of T cell receptors to HLA-DQ-gluten peptide complex [12]. On its own, a gluten-
derived peptide consisting mostly of glutamine and proline residues is actually weakly bound to 
HLA-DQ2/DQ8 heterodimers and therefore will only trigger a weak response from T cells. To 
induce high affinity, the action of tissue transglutaminase is needed to deamidate glutamine into 
glutamate, essentially converting an electrically neutral amino acid into a negatively-charged 
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amino acid. Upon tissue damage, transglutaminase enzyme is recruited and acts to immediately 
modify gluten peptides, causing greater binding affinity between HLA-DQ2/DQ8 and the gluten 
peptides, which ultimately leads to an elevated T cell response, increasing intestinal tissue 
damage. Fundamentally, the T-cell mediated response is not triggered on a full scale upon the 
encounter with the first gluten peptide, but rather in a snowball fashion [13].  
 Arguably, the most fascinating aspect about the molecular basis of the disease is the root 
of the problem itself: why do gluten-derived peptides cause an immune response to begin with? 
The answer lies in the pathogenic world. On the surface of small intestines, the extracellular 
matrix is a major barrier between our cells and all sorts of other foreign microbes. But a common 
theme in evolutionary biology is that host and parasites coevolve. In order to gain access to host 
tissues, a parasite will secrete proteases that break down the extracellular matrix of the host. As it 
turns out, like gluten, the extracellular matrix is unusually high in proline residues. Therefore, the 
presence of high levels of prolines can be interpreted by the immune system as an attempt by 
parasites to degrade the extracellular matrix and will respond accordingly [14]. 
 Although the majority of the complexity of celiac disease is contributed to its polygenic 
and epigenetic nature, the environment remains a critical factor in the onset of disease. And since 
the primary site of action in the disease are the small intestines, the role of the patient’s intestinal 
microbiome was interrogated. A study by Nistal el al., among other works, confirms the 
observation that fecal samples from celiac disease patients display different microbiota 
compositions than healthy individuals. They’ve also reported a significant difference in presence 
of Bifidobacterium bifidum between untreated celiac disease patients and healthy adults. A 
reduction in the diversity of B. bifidum was observed in treated celiac disease patients and 
healthy adults but not in untreated patients [15]. 
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 Other findings point to the possibility of certain genotypes influencing the composition of 
the microbiome. The most relevant genotype here, HLA-DQ, has been found to be in association 
with reduced B. bifidum [16]. This bacterial species is worthy of special and careful attention 
because of the anti-inflammatory effects it induces. Upon the encounter with a gluten-derived 
peptide bound to an HLA-DQ heterodimer, T cells produce pro-inflammatory cytokines such as 
TNF-α and IL-1β. It was discovered that B. bifidum induces an inhibitory effect on the secreted 
cytokines, and different strains of the bacterium correspond to varying inhibitory strength. The 
proline-rich structure of gluten proteins render them more difficult to degradation by the action 
of the body’s own proteases, allowing the proline-rich peptides to reach the lamina propria of 
small intestines. Interestingly, the B. bifidum breaks down gluten peptides further by proteolysis 
during digestion such that the gluten-derived peptides that reach the intestinal epithelia are of 
different structural patterns than the other less degraded gluten peptides normally bound by 
HLA-DQ antigens. This ultimately leads to a reduced or inhibited pro-inflammatory secretions 
by T cells [17]. The fact that gut B. bifidum alleviates the automimmune inflammatory response 
could potentially shed some light on alternative treatment methods. 
 An accurate diagnostic tool is to measure the concentration of modified gluten antibodies 
in patient serum before and after the implementation of a gluten-free diet. If a significant drop in 
gluten-specific antibodies levels is observed after introducing a gluten-free diet as opposed to 
before, then one can conclude with significant certainty that the patient has celiac disease [7]. 
Another highly effective diagnostic method would be to perform serological tests on potentially 
affected individuals while they’re on gluten-containing diet and measure the ratio of IgA 
antibodies to tissue transglutaminase. If the results are positive, a duodenal biopsy may be 
performed to confirm the results. Samples from the duodenum of the small intestines are 
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examined for signs of villous damage or other features in the lamina propria that would confirm 
the results. Moreover, a genetic test can also be used to confirm results or rule out the possibility 
of a celiac disease. An individual who is negative for both HLA-DQ2 and HLA-DQ8 is a very 
poor candidate for celiac disease [3].   
 The gluten-free diet has been the traditional method of treatment of celiac disease, and 
perhaps the most effective since patients experience symptom relief and reversal of intestinal 
tissue damage. Living in the western hemisphere where most cuisines have historically been high 
in gluten-containing foods, it can be a challenge for some patients to completely rule out gluten 
from dietary intake. However, keeping the patients well-informed about the seriousness of the 
disorder may boost their motivation to abstain from gluten. There has been research efforts 
aimed at developing effective treatment strategies, working at the molecular level, to block the 
binding sites of HLA-DQ2/DQ8 that would otherwise bind gluten peptides. The trick here is to 
design peptide analogs that bind HLA-DQ’s with higher affinity than gluten-derived peptides 
[18]. Alternative and modern treatment strategies seem to be promising and theoretically 
effective.  
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Hutchinson-Gilford	Progeria	Syndrome	
Introduction	
	 Hutchinson-Gilford	Progeria	Syndrome	(HGPS)	is	a	rare	premature	aging	disorder	that	begins	to	
manifest	within	the	first	year	or	two	of	life.	Individuals	with	HGPS	exhibit	characteristic	phenotypes	of	
aging,	such	as	lipodystrophy,	hair	loss,	skin	discoloration	or	mottling,	prominent	vasculature,	and	a	
beaked	nose	[1,2,3,4].	Due	to	the	rapid	and	early	manifestation	of	these	phenotypes,	these	individuals	
also	have	stunted	growth	in	both	height	and	weight,	skeletal	abnormalities	of	the	cranium,	mandible,	
joints,	and	fingers	(tufting),	and	cardiovascular	complications	[1,2,3,4].	Specifically,	these	individuals	
often	suffer	from	arteriosclerosis	and	atherosclerosis,	generally	resulting	in	death	around	age	13	on	
average	due	to	heart	attack	or	stroke	[1,3,4].		
	 HGPS	affects	1	in	4	million	live	births	each	year	[3].	It	was	first	described	in	1886	by	Dr.	Jonathan	
Hutchinson	and	in	1897	by	Hastings	Gilford,	but	it	was	not	until	2003	that	the	genetic	basis	was	
discovered	[5].	Studies	found	that	in	90%	of	HGPS	cases,	the	disorder	is	caused	by	a	de	novo,	non-
inherited	autosomal	dominant	point	mutation	in	the	lamin	A/C	gene	[1,6].	Due	to	this	sporadic	nature,	
no	frequency	differences	between	cultural	populations	have	been	observed	or	documented.	Current	
research	has	been	primarily	focused	on	the	cellular	effects	of	this	mutation,	how	these	effects	lead	to	
rapid	phenotypic	aging,	and	the	utilization	of	this	knowledge	in	developing	potential	treatments.	The	
continuation	of	HGPS	research	is	further	advocated	for	due	to	the	potential	knowledge	that	can	be	
gained	about	the	normal	aging	process.		
	
Genetic	Component	
	 The	lamin	A/C	gene	(LMNA)	is	located	on	chromosome	1	and	normally	functions	to	produce	A	
and	C	type	lamin	proteins	[1,2,6].	These,	along	with	type	B	lamin	proteins,	are	intermediate	filaments	
that	come	together	to	form	the	nuclear	lamina,	a	mesh-like	protein	scaffold	underlying	the	nuclear	
membrane	[3,6].	The	nuclear	lamina	supports	the	overall	structure	of	the	nucleus	and	interacts	with	
chromatin,	membrane	associated	proteins,	transcriptional	regulators,	and	nuclear	pore	complexes	[3,6].	
Through	these	interactions,	the	nuclear	lamina	has	been	shown	to	play	a	role	in	chromosomal	
compartmentalization	and	various	nuclear	activities	such	as	gene	expression	and	the	movement	of	
molecules	in	and	out	of	the	nucleus	[6].		Lamins	A	and	C	are	both	formed	from	LMNA	through	
alternative	splicing	and	have	nearly	identical	protein	sequences,	but	differ	in	length	[1,6].	In	addition,	
prelamin	A	must	go	through	several	post-translational	modification	steps	before	becoming	mature	lamin	
A,	whereas,	lamin	C	does	not	require	these	additional	processing	steps	[1,	2,6].			
The	C>T	point	mutation	that	causes	the	majority	of	HGPS	cases	is	a	synonymous	mutation	
located	in	the	third	position	of	codon	608	(position	1842)	within	exon	11	of	the	LMNA	gene	[1,3,4,6].	
Even	though	this	mutation	does	not	alter	the	amino	acid	sequence,	it	activates	a	cryptic	splice	donor	site	
that	interferes	with	normal	splicing	and	results	in	a	150	nucleotide,	50	amino	acid,	deletion	in	prelamin	
A	molecules	[1,3,6].	Within	the	deleted	region	is	a	cleavage	site,	ZMPSTE24,	necessary	for	the	removal	of	
the	c-terminal	farnesyl	group	and	conversion	of	prelamin	A	to	mature	lamin	A	[6].	As	a	result,	these	
mutated	prelamin	A	proteins,	called	progerin,	retain	the	c-terminal	farnesyl	groups,	which	cause	the	
progerin	proteins	to	remain	attached	to	the	inner	nuclear	membrane	disrupting	nuclear	structure	[4,6].	
As	progerin	accumulates,	the	nuclear	structure	becomes	increasingly	abnormal	resulting	in	
characteristic	nuclear	blebbing	and	instability	[4,6].		
Due	to	the	important	role	that	the	nuclear	lamina	plays	in	overall	nuclear	stability,	lamin	genes	
are	not	just	present	in	the	genome	of	humans,	but	are	also	present	in	many	other	organisms,	such	as	
Drosophila	and	mice	species.	Drosophila	have	two	different	lamin	genes,	lamC	that	produces	A	type	
lamins	and	DmO	that	produces	B	type	lamins	[7].	However,	the	lamin	A	proteins	produced	in	Drosophila	
are	not	farnesylated	like	in	humans.	This	prevents	the	use	Drosophila	as	model	organisms	for	HGPS	
because	the	lamC	gene	cannot	be	mutated	to	produce	progerin	[7].	Despite	these	differences,	genetic	
analysis	has	revealed	that	homologous	lamin	genes	in	Drosophila	and	vertebrates	actually	came	from	a	
common	ancestor,	indicating	a	high	level	of	conservation	[7].	This	conservation	is	further	illustrated	by	
the	presence	of	LMNA	genes	in	mice	and	primates.		
Mice	have	been	widely	used	as	model	organisms	for	HGPS	because	following	induction	of	a	
similar	C>T	point	mutation	in	the	LMNA	genes	of	mice,	they	begin	to	produce	progerin	and	exhibit	some	
of	the	same	phenotypes	as	individuals	with	HGPS	[6].	In	fact,	analysis	of	knock-out	mice	models	revealed	
that	HGPS	disease	phenotypes	are	not	caused	by	haploinsufficiency	because	even	though	these	mice	
produced	no	lamin	A,	they	did	not	have	any	nuclear	abnormalities	or	other	HGPS	associated	phenotypes	
[4].	Based	on	these	results,	it	was	determined	that	the	HGPS	mutation	works		instead	in	a	dominant	
negative	fashion	since	only	one	mutant	allele	is	required	for	disease	phenotypes	and	appears	to	out	
compete	or	inhibit	any	sort	of	potential	compensation	by	the	normal	allele	[4].	However,	these	mice	do	
not	exhibit	all	of	the	HGPS	phenotypes	present	in	humans	and	cannot	be	used	as	complete	models	of	
this	disease.		
Effect	on	Cellular	Function	
	 LMNA	is	expressed	in	nearly	all	differentiated	somatic	cells	through-out	the	body	so	any	
mutation	in	this	gene	can	affect	the	function	of	many	different	cell	types,	especially	bone	cells	and	
fibroblasts	of	skin,	muscle,	and	vascular	tissue	[1,2,6].	In	contrast,	cells	of	the	nervous	system	have	been	
found	to	express	LMNA	at	substantially	lower	levels	than	other	cells	of	the	body	[1,4,6].	As	a	result,	the	
production	of	progerin	in	nerve	cells	is	minimal,	which	may	explain	why	HGPS	individuals	show	no	
indication	of	neural	deficits	[1,4,6].		
As	previously	mentioned,	progerin	causes	abnormal	nuclear	structure	because	it	remains	
farnesylated	and	subsequently	attached	to	the	inner	nuclear	membrane.	This	disruption	to	the	nuclear	
structure	is	further	intensified	as	progerin	accumulates	within	the	cell	because	progerin	molecules	come	
together	to	form	insoluble	cytoplasmic	aggregates	that	bind	to	the	nuclear	membrane	and	cause	the	
nuclear	blebbing	observed	later	on	in	the	progression	of	the	disease	[8].	These	progerin	aggregates	also	
interfere	with	proper	cell	division	because	lamin	A	is	normally	present	in	an	unpolymerized	state	during	
mitosis	[8].	As	a	result,	this	abnormal	membrane	morphogenesis	can	cause	chromosome	misalignment	
during	mitosis	as	well	as	disrupt	proper	nuclear	division,	which	can	lead	to	improper	chromosome	
separation	and	binucleation	[8].	Mitosis	was	also	observed	to	be	further	disturbed	by	chromosome	
lagging	during	anaphase	in	HGPS	cells	[8].	
	 Normal	lamin	A	is	known	to	interact	directly	with	chromatin	at	specific	heterochromatic	regions.	
These	interactions	promote	proper	chromosomal	compartmentalization	within	the	nucleus	as	well	as	
play	a	potential	role	in	gene	expression	[3].	In	a	study	done	by	McCord,	progerin	was	found	to	interact	
differently	with	chromatin	than	normal	lamin	A	proteins	causing	an	altered	pattern	of	H3K27me3	at	
numerous	chromatin	locations	[3].	This	histone	modification	is	a	repressive	mark	associated	with	
facultative	heterochromatin	commonly	used	in	the	regulation	of	gene	expression	[3].	Further	analysis	
revealed	that	these	disease-related	epigenetic	alterations	were	present	at	several	promoter	sites,	
resulting	in	deviations,	both	higher	and	lower,	from	normal	levels	of	expression	in	corresponding	genes	
[3].	These	histone	alterations	were	also	shown	to	result	in	loss	of	normal	chromosomal	
compartmentalization	because	they	prevented	normal	overall	association	of	chromatin	with	the	nuclear	
lamina	[3].	The	nuclear	lamina	is	also	believed	to	control	the	binding	and	release	of	lamin-associated	
proteins	from	the	nuclear	periphery,	which	most	likely	regulate	the	expression	of	developmentally	
regulated	genes	by	either	silencing	or	activating	transcription	[9].	Progerin	was	also	shown	to	affect	
these	protein-chromatin	interactions	altering	gene	expression	[9].	McCord	further	concluded	that	these	
modifications	to	H3K27me3	occurred	well	before	nuclear	blebbing	in	HGPS	cells	indicating	that	these	
alterations	arise	very	early	on	and	may	be	a	potential	cause	for	the	rapid	phenotypic	manifestation	of	
this	disease	[3].		
	 In	a	proteomic	study,	Rivera	found	dramatic	differences	in	the	level	of	certain	proteins	found	in	
HGPS	fibroblasts	compared	to	control	fibroblasts	[6].	An	upregulation	of	glycolytic	proteins	and	a	
downregulation	of	proteins	involved	in	oxidative	phosphorylation,	ATP	synthase	(complex	V),	and	
translational	apparatus	proteins,	ribosomal	proteins,	was	found	in	HGPS	fibroblasts	[6].	These	proteomic	
alterations	in	HGPS	cells	indicate	an	evident	switch	from	oxidative	to	glycolytic	metabolism	due	to	
defective	oxidative	phosphorylation.	This	defect	in	cell	metabolism	is	called	mitochondrial	dysfunction	
and	is	believed	to	contribute	to	the	premature	organ	decline	in	HGPS	individuals	[6].	These	same	results	
were	also	found	through	proteomic	analysis	of	both	heterozygous	and	homozygous	progeriod	mouse	
models	and	ZMPSTE24-/-	mice	models	[6].	The	ZMPTSTE24-/-	mice	do	not	produce	progerin,	but	do	lack	
the	cleavage	site	necessary	for	the	removal	of	the	farnesyl	group	so	are	unable	to	convert	prelamin	A	
into	mature	lamin	A.	Using	these	mice,	it	was	illustrated	that	build-up	of	prelamin	A	has	similar	effects	
on	cellular	metabolism	as	the	build-up	of	progerin	[6].		
	 Upon	analysis,	Decker	found	that	the	overall	telomere	lengths	in	HGPS	cells	did	not	follow	the	
same	chromosome	specific	pattern	observed	in	normal	cells,	suggesting	a	more	random	arrangement	of	
chromatin	in	HGPS	cells	[1].	One	such	deviation	discovered	was	that	on	average	the	telomeres	were	
shorter	in	HGPS	cells	and	at	least	one	chromosome	in	every	HGPS	cell	analyzed	had	telomeres	shorter	
than	the	threshold	for	detection,	which	was	not	observed	in	any	of	the	control	cells	[1].	However,	the	
chromosome	in	which	these	extremely	short	telomeres	occurred	was	not	consistent	and	varied	between	
HGPS	cells	[1].	Since	telomeres	become	shorter	with	each	replication	and	cell	division,	telomere	length	
is	a	critical	factor	in	how	many	times	a	cell	can	divide.	Therefore,	it	is	believed	that	the	overall	shorter	
telomeres	in	HGPS	cells	lead	to	the	premature	senescence	that	cause	arterial	changes	and	eventual	
heart	attack	or	stroke	of	HGPS	individuals	[1].	It	is	not	yet	clear	why	HGPS	cells	possess	shorter	
telomeres,	but	it	has	been	found	through	studies	of	the	normal	aging	process	that	shorter	telomeres	
may	actually	induce	the	production	of	progerin	in	normal	cells	later	in	life	[2].	This	gives	insight	into	a	
potential	mechanism	behind	the	very	rapid	accumulation	of	progerin	and	subsequent	phenotypic	
manifestation	of	HGPS.		
	 Progerin	was	also	found	to	negatively	affect	the	multipotency	and	differentiation	of	
mesenchymal	stem	cells	(MSCs)	by	increasing	the	sensitivity	of	MSCs	to	hypoxia	[10].	This	causes	an	
overall	shortage	of	mesenchymal	stem	cells	in	HGPS	patients,	which	are	necessary	for	tissue	
replenishment,	leading	to	an	overall	reduction	in	the	amount	of	certain	differentiated	cell	types	[10].		
This	same	affect	was	seen	on	vascular	smooth	muscle	cells,	which	presented	with	increased	DNA	
damage	and	nuclear	abnormalities	in	HGPS	cells	[10].	These	defects	are,	therefore,	likely	contributors	to	
the	serious	cardiovascular	complications	associated	with	HGPS.		
Clinical	Aspects	and	Associated	Diseases	
	 This	disease	is	part	of	a	group	of	12	diseases	known	as	laminopathies,	each	one	resulting	from	a	
different	mutation	in	the	LMNA	gene	that	affects	the	proper	processing	of	prelamin	A	[2,6].		Despite	this	
commonality,	these	diseases	all	present	with	a	distinct	set	of	clinical	phenotypes	associated	with	various	
tissues	including	myopathy,	cardiomyopathy,	lipodystrophy,	neuropathy,	and	premature	aging	[2].	HGPS	
is	generally	diagnosed	prior	to	two	years	of	life	based	on	stunted	growth,	lipodystrophy,	and	overall	
failure	to	thrive	[3,4].	These	initial	signs	are	rapidly	followed	by	the	onset	of	other	characteristic	
phenotypes	associated	with	aging	[4].	Genetic	testing	for	the	associated	LMNA	mutation	can	then	be	
performed	to	confirm	the	visual	diagnosis.		
	 HGPS	exhibits	complete	penetrance.	Due	to	the	dominant	negative	affect	of	this	mutation,	the	
presence	of	only	one	mutated	allele	is	necessary	to	cause	HGPS	and	will	always	result	in	HGPS	[4].	
Potentially	due	to	the	sporadic	origin	of	this	mutation,	most	individuals	with	HGPS	are	heterozygous	for	
the	mutated	allele	[6].	This	makes	comparison	of	phenotypic	severity	between	heterozygous	and	
homozygous	individuals	extremely	difficult	to	achieve.	However,	using	both	heterozygous	and	
homozygous	progeriod	mouse	models,	Rivera	was	able	to	reveal	that	the	effects	of	progerin,	with	regard	
to	mitochondrial	dysfunction,	is	both	dose	and	time	dependent	[6].	Phenotypic	comparison	between	
heterozygous	and	homozygous	progeriod	mice	revealed	that	homozygous	mice	exhibited	disease	
phenotypes	at	an	earlier	age	and	with	increased	severity	than	heterozygous	mice	[6].	Younger	
heterozygous	mice,	10	weeks	old,	also	showed	less	severe	phenotypes	and	mitochondrial	dysfunction	
than	older	heterozygous	mice,	32	weeks	old	[6].	Together	these	results	show	how	the	amount	of	
progerin	affects	the	phenotypic	severity	of	the	disease.		
	 Progerin	has	been	found	in	cells	of	individuals	of	advanced	ages	and	therefore	is	believed	to	play	
a	role	in	the	normal	aging	process	[2].	In	a	study	done	by	McClintock	analyzing	the	aging	process	of	
normal	skin	cells	compared	to	HGPS	cells,	progerin	was	not	only	found	in	normal	skin	cells,	but	also	
determined	to	increase	in	an	age-dependent	manner	just	as	in	HGPS	cells	[2].	However,	the	level	of	
progerin	was	still	substantially	lower	in	normal	cells	of	even	the	most	advanced	ages	compared	to	the	
level	of	progerin	in	HGPS	cells	[2].	Although,	the	effects	may	not	be	as	drastic	in	normal	cells	as	they	are	
in	HGPS	cells,	studies	regarding	HGPS	have	given	incredible	insight	into	the	process	of	aging.	Telomeres	
have	been	shown	to	shorten	over	the	lifetime	of	an	individual	and	act	as	a	sort	of	molecular	clock	
controlling	the	lifespan	of	cells	and	of	individuals	as	a	whole	[1].	As	previously	mentioned,	it	is	believed	
that	the	shortening	of	telomeres	due	to	replicative	damage	and	cellular	division	may	actually	cause	the	
activation	of	the	cryptic	splice	site	in	certain	cells	leading	to	the	production	of	progerin	in	normal	cells	at	
advanced	ages	[1,2,6].	This	progerin	production	and	accumulation	would	in	turn	cause	the	same	cellular	
affects	observed	in	HGPS	cells	to	occur	in	normal	cells,	thereby	serving	as	a	potential	explanation	for	the	
increased	incidence	of	nuclear	abnormalities,	mitochondrial	dysfunction,	and	reduction	in	
transcription/DNA	repair	seen	in	the	normal	cells	of	older	individuals	[2,6].		
Health	Issues	and	Treatments	
	 The	prognosis	for	individuals	with	HGPS	is	very	bleak,	with	a	100%	fatality	rate	[4].	As	of	now,	
there	is	no	cure	for	this	disease	and	most	of	the	treatments	are	geared	towards	pacifying	the	age	
associated	ailments	caused	by	this	disease.	Studies	have	shown	that	HGPS	individuals	experience	drop	
out	of	smooth	vascular	muscle	cells,	reduced	elasticity	and	thickening	of	arterial	walls,	and	reduced	
vascular	compliance	resulting	in	high	blood	pressure	[4].		As	a	result,	a	great	deal	of	emphasis	is	placed	
on	treating	these	cardiovascular	complications,	however,	almost	all	individuals	eventually	die	during	
their	adolescent	years	from	heart	attack	or	stroke	[4].	Growth	hormones	are	also	administered	in	
attempt	at	increasing	the	overall	height	and	weight	of	these	individuals	[4].	This	treatment	has	proven	
to	be	successful	to	some	extent,	but	a	large	gap	in	overall	growth	still	remains	in	comparison	to	healthy	
children	of	the	same	developmental	age	[4].	Other	ailments	commonly	exhibited	by	individuals	with	
HGPS	include	hearing	loss,	hyperopia,	and	joint	abnormalities.	These	individuals	remain	surprisingly	
mobile,	however,	despite	joint	abnormalities	and	cardiovascular	issues,	with	majority	testing	within	the	
average	mobility	range	for	their	age	[4].		
	 There	are	several	treatments	currently	undergoing	clinical	trials	aimed	at	combating	different	
molecular	components	of	the	disease.	One	such	treatment	focuses	on	the	use	farnesyl	transferase	
inhibitors,	which	inhibit	the	addition	of	the	farnesyl	group	to	prelamin	A	molecules	during	the	early	
post-translational	modification	steps	[4].	By	inhibiting	the	addition	of	the	farnesyl	group,	the	mutated	
prelamin	A	proteins	will	no	longer	remain	permanently	attached	to	the	inner	membrane	allowing	for	the	
restoration	of	nuclear	structure	[4].	Clinical	trials	for	this	type	of	drug	showed	increase	weight	gain	and	
fat	tissue,	improved	vascular	stiffness,	and	bone	mineralization	resulting	in	reduced	fracture	rate	[4,11].	
The	administration	of	this	drug	also	extended	the	lifespan	of	individuals	on	average	by	about	1.6	to	2.4	
years	[11].	However,	these	outcomes	only	occurred	in	some	treated	individuals,	but	not	all	[11].	Another	
treatment	undergoing	clinical	trials	is	the	use	of	isoprenylation	inhibitors.	In	mice	models,	it	was	shown	
that	preventing	progerin	isoprenylation	increased	ATP	synthesis	and	reduced	overall	mitochondrial	
dysfunction	[6].	The	potential	use	of	isoprenylation	inhibitors	in	combination	with	farnesyl	transferase	
inhibitors	has	also	been	proposed	and	shown	to	enhance	the	beneficial	outcomes	of	farnesyl	transferase	
inhibitors	in	early	trial	stages	[6].	However,	the	use	of	isoprenylation	inhibitors	individually	and	in	
combination	with	farnesyl	transferase	inhibitors	is	still	under	evaluation.		
	 Rapamycin	is	another	proposed	drug	currently	undergoing	clinical	trials	and	evaluation.	The	
major	target	of	rapamycin	in	the	body	is	a	central	regulator	of	cell	growth	and	various	other	cell	
processes	known	as	the	mammalian	target	of	rapamycin	(mTOR)	[12].	However,	rapamycin	has	also	
shown	to	induce	macroautophagy,	which	is	the	normal	process	used	by	cells	to	get	rid	of	damaged	or	
unnecessary	components	through	lysosomal	degradation	[12].	Rapamycin	has	also	been	shown	to	
increase	the	solubility	of	progerin	that	has	formed	cytoplasmic	aggregates	[12].	By	promoting	autophagy	
and	dissolution	of	progerin	aggregates,	rapamycin	has	proven	successful	in	decreasing	the	amount	of	
progerin	accumulation	in	HGPS	cells.	This	increase	in	progerin	turn	over	has	allowed	for	improvement	
and	even	reversal	of	nuclear	blebbing,	restored	H3K27me3	modifications,	and	extended	the	cellular	
lifespan	by	an	average	of	30	days	thereby	successfully	postponing	cellular	senescence	[12].		
	 In	addition	to	the	treatments	currently	undergoing	evaluation,	there	are	several	more	
prospective	treatments	not	yet	ready	for	actual	application	or	clinical	trials	due	to	an	increased	level	
complexity	[5].	These	treatments	include	RNA,	gene,	and	cell	replacement	therapies.	RNA	therapy	would	
involve	the	removal	or	inhibition	of	the	alternative	splice	site	activated	by	the	mutation	whereas	
targeted	gene	therapy	would	involve	the	actual	repair	of	the	mutated	gene	outside	of	the	body	followed	
by	its	reintroduction	into	the	body	[5].	Cell	replacement	therapies	would	focus	primarily	on	the	use	of	
matched	normal	cells	or	stem	cells	from	HGPS-iPS	cell	that	have	been	genetically	corrected	[5].	Although	
different	in	methodology,	all	present	steep	obstacles	that	will	take	a	great	deal	of	effort	and	time	to	
overcome	prior	to	actual	application.	However,	these	treatments	may	hold	the	key	to	a	more	
permanent	or	even	complete	remedy	to	HGPS.		
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 Lesch-Nyhan Syndrome (LNS) was not an officially diagnosed disease until 1964 in the 
United States of America when two physicians, Lesch and Nyhan, recognized a pattern of 
abnormal neurological function, self-mutilating behavior, and exceptionally high levels of uric 
acid in the urine of two young brothers (Lesch & Nyhan, 1964). It is not surprising that the 
recognition of LNS did not come until the 1960s. The disease is an “Orphan Disease”, meaning it 
is exceptionally rare. For example, in the United Kingdom, a country with fifty-six million 
people, there is an average of only four new cases per year (McCarthy, 2006). Overall, one out of 
eight hundred thousand live births will be affected by Lesch-Nyhan (Hall, 2001). In none of the 
research was it mentioned any specific population or geographical region being more prone to or 
having higher incidence rates of LND. This could be due to the large percentage of mutations 
leading to LND being de novo mutations instead of mutations being passed though families as 
will be discussed later in this paper.  
 Soon after Dr. Lesch and Dr. Nyhan published their work describing the syndrome, more 
cases were reported and studied. From the fifth family to be studied with a history of the 
syndrome, the largest family being studied in that time period, a pedigree was created. 
Combining the information from the five families, a team at the University of Virginia School of 
Medicine was able to deduce that the inheritance pattern in LNS was X-linked recessive 
(Shapiro, 1966). This was determined as only boys were affected and the ratio matched what was 
predicted, one in four boys affected from unaffected parents. Females thought to be carriers due 
to having an affected son showed slightly higher levels of uric acid in urine (Shapiro, 1966); this 
supports the hypothesis of X-linked transmission as the phenotype of heterozygotes is slightly 
altered.   
Male to male dominant transmission as a pattern of inheritance was eliminated as a 
possible hypothesis because of the evidence of female carriers having differing levels of uric acid 
than average and because most boys with LNS  at the time of this research were institutionalized 
very early in childhood or died in infancy (Shapiro, 1966), leaving them unable to pass on 
genetic information. Male to male dominant transmission could also be eliminated as a potential 
hypothesis due to the presence of rare affected females. In one such case, an affected female had 
a monozygotic twin who was unaffected by the disease. It was able to be determined through 
fibroblast study that in the affected twin, the wild type allele has been silenced throughout the 
body while in the unaffected twin the mutant allele had undergone the X-inactivation (Gregorio, 
2005).  
 With the mode of inheritance determined through pedigree analysis and confirmed later 
with the study of affected females, scientists began to search for the cause of this disease. Due to 
the excessive amounts of uric acid produced by patients manifesting symptoms of LNS, it was 
assumed by a team headed by J. Edwin Seegmiller that the disease must be caused by an enzyme 
involved in purine metabolism losing its function (Seegmiller, 1967). The enzyme responsible 
was indeed involved in purine metabolism: hypoxanthine-guanine phosphoribosyltransferase 
(Seegmiller, 1967).   
 We know today that the gene that codes for this enzyme is quite large, fourty-four kb, and 
contains nine exons in humans (Lapucci, 2006). Because LNS is caused by a single gene 
mutation, an affected individual does not show a karyotype different than an unaffected 
individual. This gene leading to LNS when mutated is called the HPRT gene, and it is located on 
the long arm of the X chromosome at Xq26 (Torres G. P., 2012). In the year 2003, over two 
hundred mutations had been observed within the HPRT gene leading to the symptoms of LNS, 
and it was found that thirty percent of all mutations in the HPRT gene are de novo (Ohdoi, 
2002). In 2015, twenty-seven new mutations at the HPRT locus were identified in a single study, 
bringing the total of known HPRT mutations leading to LNS to over four hundred (Ceballos-
Picot, 2015), which further emphasizes how this region of the X chromosome is prone to new 
mutations or, if it is mutating at the same rate as the rest of the genome, the mutations are 
occurring in areas where the affects produce a noticeable phenotype.  
 When the mutation at the HPRT gene is large scale, such as the deletion or a frame shift, 
the phenotype associated with LNS will always be fully displayed in males who only possess the 
mutant copy or in females who have the wild-type copy inactivated. Some of these large scale 
mutations can be caused by incorrect splicing regulation as was the case in the twin study 
discussed previously (Gregorio, 2005). The phenotype is always displayed because these 
mutations lead to the production of hypoxanthine-guanine phosphoribosyltransferase enzymes 
that have completely lost their function (Ceballos-Picot, 2015). Without a functional 
hypoxanthine-guanine phosphoribosyltransferase enzyme, the patient is not able to properly 
metabolize purines, leading to the build up of uric acid (Lapucci, 2006). This build up of uric 
acid was a part of the original observations by Lesch and Nyhan which also included 
“hyperuricema, mental retardation, choreoathetosis and self-destructive biting” (Lesch & Nyhan, 
1964). Other phenotypes now associated with LNS are severe muscular dystonia and any form of 
self-mutilation in addition to biting (Gregorio, 2005).  
Clinically, it can be difficult to diagnose the forms of self-mutilation in LNS compared to 
self mutilation that occurs with other neurological abnormalities such as autism. An important 
study was done to shed light on this aspect of LNS. The study, preformed by a team led by Scott 
Hall in 2001, showed that in in patients with LNS the self-mutilation is almost exclusively 
sudden and violent, even initially when the behavior is first occurring. In patients with autism, 
however, the self-mutilating behaviors usually increase gradually (Hall, 2001).  It was also found 
in this study that episodes of self-mutilation correlated with the child being left alone without 
interaction with a caretaker (Hall, 2001), which the authors believe could be a sign that some of 
the self-mutilating LNS phenotype may be tied to environmental factors.  
 In some individuals that exhibit the phenotype for LNS there is no mutation within the 
HPRT gene. Using Real time PCR it was discovered that there was a mutation in the regulatory 
sequence, and this mutation prevented the HPRT gene from being transcribed (Torres G. P., 
2012) .  After testing both parents, the mother was determined to be a carrier for this regulatory 
mutation (Torres G. P., 2012). Studies such as this further confirm that LND is is transmitted 
though X-linked inheritance.  
 It is likely that this wide array of phenotypes affecting the muscular, renal, and 
neurological functions of the body occur when the HPRT gene is no longer coding for a working 
hypoxanthine-guanine phosphoribosyltransferase enzyme because purines are essential in all 
tissues of the body and not limited to one specific cell or tissue type (McCarthy, 2006). For 
example, patients with LND have been shown to have significant decreases in their white and 
gray brain matter (Schretlen, 2013). Regions especially affected where the basal ganglia, 
frototemporal, and the limbic system. These decreases in brain matter could imply that deficient  
purine metabolism leading to the buildup of incorrect cellular products could affect brain growth 
and development, especially in the regions previously mentioned (Schretlen, 2013).  
Individuals who have a mutation in the HPRT gene that does not lead to complete loss of 
hypoxanthine-guanine phosphoribosyltransferase enzyme function show a less severe phenotype 
known as Lesch-Nyhan Variants (Ceballos-Picot, 2015). These mutations cause a phenotype that 
has lower levels of cognitive impairment and no self-mutilating behaviors. Because these 
phenotypes belong to a different disorder than LNS, it can be concluded that the phenotype range 
for LNS is very small and without all of the symptoms, an individual does not actually have LNS 
but instead a less severe variant disorder.  
 Currently, there is no cure for the phenotypes associated with LNS. Instead, efforts are 
made by caregivers to manage physical and behavioral symptoms according to lesch-nyhan,org. 
One of main symptoms that leads to a diagnosis of LND, the overproduction of uric acid, can be 
managed with the use of a drug called allopurinol (Torres P. P., 2007). Allopurinol inhibits the 
enzyme xanthine oxidase to prevent the body from synthesizing excessive amounts of uric acid. 
The study preformed by Torres, Prior, and Puig showed that even after long term use of 
allopurinol, patients did not have any adverse side effects, and the drug maintained its 
effectiveness. It was found that with the use of this drug, patients were able to consistently have 
seventy-four percent less uric acid excretion compared to their baseline levels. Managing the uric 
acid levels in patients and returning them closer to the normal range does not lessen the other 
symptoms of the disease such as self-mutilation, however (Hall, 2001).  
 Currently, behavioral therapy is the only method that can be used in an attempt to control 
the self mutilating behavior found in LNS, according to lesch-nyhan.com. Pharmaceuticals, such 
as s-adenosylmethionine, have been shown to provide little improvement or even worsened 
behavior in LND patients (Dolcetta, 2013). In another study, 5-hydroxytryptophan in 
combination with a peripheral decarboxylase inhibitor carbidopa and imipramine was used in an 
attempt to control the self-mutilating behavior is LNS (Nyhan J. K., 1980). This treatment 
appeared to be successful initially, but after three months each of the patients became immune to 
the pharmacological effects, rending the treatment ineffective.  
 When behavioral therapy is used, it is important that it does not involve negative 
punishment. Studies have shown that when negative punishment, such as an electric shock, 
follow the self-mutilating behavior, the frequency of the self-mutilating behavior increases (Zilli, 
2008). The authors of the study suggest that early in the progression of LNS, individuals 
accidently injure themselves due to the lack of motor coordination associated with muscular 
degeneration. After the accidently injury, improper dopamine signals in the basal ganglia 
reinforces these behaviors, leading to individuals with LNS to begin to regularly self-mutilate 
(Zilli, 2008). Therefore, when a negative punishment is applied following self-mutilation, it acts 
as a reinforcement of the behavior because the improper dopamine signals are further stimulated.  
 In a review article published in 2000, restraint, in the form of splits, wheelchairs, and 
keeping the patient from any sharp objects was the most common form of behavioral 
modification (Olson, 2000). In fact, the removal of these restraints often lead to noticeable 
distress in patients with LNS and increased levels of self-mutilating behavior. Treatments 
including extinction, systematic desensitization, and play therapy used in conjunction were 
shown to decrease the self-injurious behavior in several separate studies to the point where the 
child no longer needed to be restrained (Olson, 2000). Hall found in his research that positive 
and continued interactions with caregivers could also reduce the frequency of self-mutilating 
behaviors (Hall, 2001). Even though there are some behavioral treatments shown to be effective, 
many children still have all of their teeth extracted to prevent lip biting, cheek biting, and finger 
biting (Hall, 2001).  
 There was a significant study published in 2015 by a team lead by Dr. Piedimonte that 
shows potential to permanently treat the self-mutilating behavior associated with LNS. In this 
case study, the team of doctors applied deep brain stimulation consistently to a twenty-nine-year-
old patient via a bilateral electrode implant. The patient showed progressive improvement and 
soon did not need his hands tied to prevent self-mutilation. Caretakers also reported a better 
overall mood and willingness to help with his own needs. Five years later, there were no adverse 
side affects and the self-mutilation behavior had been totally eliminated in the patient 
(Piedimonte, 2015).  
 Due to the severe neurological impairments, self-mutilating behaviors, and stress on the 
renal system due to the high levels of uric acid being excreted, it is not surprising that individuals 
with LNS do not have a normal life expectancy; most individuals only survive into the second or 
third decade of their life, and this lifespan length is only possible with diligent treatment and 
therapy by the patient’s family (Nyhan O. J., 2014).  
 Because of the severe phenotypes, burden of care on family members, and short life 
expectancy with low qualify of life by people suffering from LNS, many families with a history 
of LNS undergo genetic testing in an attempt to avoid having children with this disease. Initially, 
embryos with LNS were identified during pregnancy by culturing amniotic fluids (Halley, 1977). 
The amniotic fluids were cultured on a coverslip and the autoradiographic analysis was available 
a week later. By observing the karyotypes and the autoradiograohic analysis, a unaffected male, 
affected male, and unaffected female were all correctly identified (Halley, 1977). However, the 
amniotic fluids were not received until the mothers were in approximately their twentieth weeks 
of pregnancy, and then it took almost two weeks to get the results back. This led the mother with 
the affected male fetus to have an abortion at twenty-two weeks (Halley, 1977).  
Today, there is technology available to completely avoid a pregnancy with a fetus 
affected by LND instead of terminating an affected pregnancy, a practice that is much more 
ethically accepted in current culture. This is done using in vitro fertilization (IVF). In a study 
published in 1999, researchers were able to create blastocysts using the egg and sperm of parents 
who already had one affected son using standard IVF procedure (Ray, 1999). After the 
blastocysts had been dividing for three days, the healthiest were chosen to be genetically tested. 
This genetic test was a single cell PCR amplification of DNA from a biopsied cell from the 
healthy blastocysts. The PCR primers were designed to anneal to the region just before exon 8 in 
the HPRT gene as the mother and affected son had both been previously found to have a deletion 
in exon 8 (Ray, 1999). After five rounds of IVF treatment, a successful pregnancy and delivery 
of an unaffected infant occurred (Ray, 1999). However, in all of the cycles there were always 
several blastocysts that did not survive the biopsy procedure, making this method potentially 
very difficult to preform successfully without patients who are willing to undergo multiple cycles 
of IVF like the couple in the study. By 2003, this problem seemed to have been somewhat 
reduced as a team in Australia were able to fertilize and biopsy five blastocysts with no 
complications and implant two with the highest chances of surviving. This lead to the delivery of 
a healthy, non-carrier, baby girl (Cram, 2003).  
When studying LNS and the HPRT gene, it is possible to use animal models because the 
HPRT gene is in a highly conserved region. According to ncbi.gov, the gene is conserved 
between humans, Rhesus monkeys, chimpanzees, dogs, cows, mice, chickens, zebra fishes, and 
frogs. 156 other organism contain an ortholog of the human HPRT gene. The animal model most 
widely used is the mouse. In a review article published in 2016, it is pointed out that the animal 
models of Lesch-Nyhan have some limitation due to mice having slightly different purine 
metabolism pathways than humans. The models can only study one aspect of the disease at a 
time, either the dysfunction in purine metabolism or the neurological problems leading to self-
mutilation (Knapp, 2016). The mouse models have been useful for studying the importance of 
the neurotoxins and depleted dopamine in the brain at different points in development. It has 
been found that when young mice are exposed to the neurological conditions associated with 
LNS that cause damage to the basal ganglia, they develop severe self-mutilating behavior similar 
to the human phenotype (Knapp, 2016). When the mice are not exposed to this until they are 
adolescents, however, they do not develop self-mutilating behavior despite similar levels of 
damage caused to the basal ganglia (Knapp, 2016). Further research on this topic could greatly 
increase scientists understanding of brain development in babies and children with a deficient 
HPRT gene.  
Because the mouse models are not completely representative of the human disease as 
discussed above, research is now being done on human embryonic stem cells (Urbach, 
Schuldiner, & Benvenisty, 2004). By using human cells that have been mutated to have the 
HPRT mutation that appears in LNS, scientists are hopeful that they will be able to learn even 
more about this disease. This knowledge could lead to a better understanding and future areas for 
treatment for individuals affected with LNS.  
There has also been a recent push for gene therapy as a cure for LNS as it is a disease 
caused by a single gene mutation. However, gene therapy for the HPRT gene is not as easy as it 
sounds. Because LNS causes severe neurological problems, the HPRT gene would have to be 
replaced in brain tissue. This is currently not practical due to the blood-brain barrier; scientists do 
not have a vector for inserting the HPRT gene that can cross this barrier (Cattelan, Dolcetta, 
Hladnik, & Fortunati, 2013). In 2013, however, scientists did have success with replacing the 
HPRT enzyme in the body instead of replacing the gene (Cattelan, Dolcetta, Hladnik, & 
Fortunati, 2013). They did this by attaching the enzyme that was created in the lab to a protein 
that had the ability to pass through biological membranes, which allowed it to enter deficient 
cells. This was all done in vivo, meaning the patient would have to return for continued therapy 
(Cattelan, Dolcetta, Hladnik, & Fortunati, 2013). This makes enzyme therapy a less appealing 
option than gene therapy, but until a vector can be created or discovered to cross the blood brain 
barrier, enzyme replacement therapy will continue to be as close to gene therapy as scientists can 
get.  
 Research being tested in clinical trials is very slow for LNS; on the government website 
for clinical trials, clinicaltrials.gov., there have been only four studies since 2003. One of these 
studies was not able to be completed and one did not have results. The two studies that attained 
results were for the drug Ecopipam. Ecopipam was a drug meant to reduce self-mutilation. Both 
of these clinical trials were sponsored by a pharmaceutical company. In the original clinical trial, 
the majority of the participants showed some improvements with mild side affects such as nausea 
and respiratory infection. In the second trial when Ecopipam was compared to the placebo, 
however, the study had to be terminated due to serious side affects experienced by the group 
receiving Ecopipam such as dystonic crisis and unusual somnolence.   
 The slowness of current research is most likely due to the limited number of individuals 
in the population affected with LNS. The amount of government funding on LNS is not enough 
to be recorded as an independent category, meaning less than a million dollars were provided to 
study the disease. Without government funding, all of the money for research has to come from 
independent organizations.  
 In summary, LNS is an inherited X-linked recessive disorder. It is always expressed in 
affected males and rarely in carrier females. The phenotype is caused by a large scale mutation in 
the HPRT gene, leading to a lack of the enzyme hypoxanthine-guanine 
phosphoribosyltransferase. Without this enzyme, individuals are not able to correctly metabolize 
purines. This leads to severe phenotypes of self-mutilation, neurological conditions, dystonia, 
and high levels of uric acid in the body. These symptoms will be expressed in the first years of 
life. Thus far, research has been primarily based on genetic testing and IVF treatments to prevent 
couples from having affected children. There is no cure for LNS, but improvements have been 
made in managing the symptoms of the disease.  
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 Marfan syndrome was first described in 1896 by French physician Antoine Marfan, who 
observed one of the characteristic symptoms, disproportionately long limbs, in a young girl who 
he was treating. The genetic basis of the syndrome was discovered nearly sixty years later in a 
study of patients with Marfan syndrome and their families. In 1991 (Dietz et al, 1991), it was 
found that mutation of the FBN1 gene on chromosome 15 is responsible for the symptoms that 
characterize Marfan syndrome.  
 The FBN1 gene encodes fibrillin-1, which is a large protein with several functions (Dietz 
et al., 2005). Fibrillin-1 is exported from the cell into the extracellular matrix, which is made up 
of molecules outside of the cell whose primary function is to connect cells to each other. One of 
the main functions of fibrillin-1 in the extracellular matrix is as a structural component of 
microfibrils. Microfibrils are important parts of two types of fibers in the extracellular matrix: 
elastic and oxytalan fibers. These fibers provide stability and some elasticity to tissue. Along 
with their structural function, these fibers also play an important role in the regulation of growth 
factor concentration (Bonetti, 2009). 
 Marfan syndrome is caused by the mutation of the FBN1 gene (Dietz et al., 1991). Over 
600 different Marfan-causing mutations of the FBN1 gene have been observed, varying in the 
number of nucleotides changed and the severity of symptoms they cause. These mutations take 
the form of frameshifts, splice errors, nonsense mutations, and missense mutations, which form 
the majority of mutations found in the FBN1 gene (Hilhorst-Hofstee et al., 2010). While the 
exact type of mutation may vary, the mutations that cause Marfan syndrome cause a misformed 
fibrillin-1 protein to be created. The misformed protein will not be able to fold properly, leading 
to improper association with the other components of the microfibrils (Robinson & Godfreyb, 
2000). Since the fibrillin-1 is unable to enter the proper conformation, the strength of the 
microfibrils is weakened. This also greatly harms the ability for transforming growth factor beta 
(TGF-β) to bind to the fibers (Bonetti, 2009).  
 The inability of TGF-β to bind to microfibrils causes an excess amount of free TGF-β in 
the body. The effects of excess TGF-β are where much of the new research on Marfan syndrome 
is investigating. High levels of TGF-β cause lower muscle mass and increase the level of elastin 
degradation. Elastin is another component of the elastic fibers. Degradation of elastin combined 
with a misformed fibrillin-1causes further weakening of connective tissue. Some have proposed 
that it is the high levels of TGF-β that cause many of the symptoms of Marfan syndrome rather 
than the misformed fibrillin-1 (Benke et al., 2013). 
 Marfan syndrome is an autosomal dominant disorder, which means that an affected 
parent has a 50% chance of passing the disorder onto each child they have. While most patients 
with the disorder have a parent or other close family member with the disorder, it is estimated 
that anywhere from 15-30% of the cases are caused by a new mutation that was not present in 
either parent. The disease affects males and females equally and does not seem to be more 
prevalent in any one race or ethnicity (Dietz et al., 2005). About 1 in 5000 people has Marfan 
syndrome. A similar syndrome has been observed in mice with mutations to the homolog to the 
FBN1 gene in that species (Pereira et al., 1999). 
 The symptoms of Marfan syndrome are highly variable. This is thought to be the case for 
two main reasons. The first is the nature of the mutation of the FBN1 gene. While most of the 
mutations that cause Marfan syndrome are caused by the change of just one base, it is thought 
that the base or bases that are mutated can lead to somewhat different symptoms (Aoyama et al., 
1995). The exact correlation between genotype and phenotype is not well understood in Marfan 
syndrome. The phenotype is variable even in patients who have had complete deletions of the 
FBN1 gene (Hilhorst-Hofstee et al., 2010) If a complete deletion of the gene also leads to 
variable symptoms, it seems clear that environmental, genetic, or epigenetic factors may be 
having some sort of effect on the phenotype as well. This would seem to make studying the 
differential effects of mutations on phenotype very difficult and would make results of such 
studies unreliable at best. Perhaps the most well understood correlation between genotype and 
phenotype in Marfan syndrome comes in those who have deletions in both copies of the FBN1 
gene. These cases are highly rare as they require both parents to have Marfan syndrome and pass 
the affected allele onto the child or for two de novo mutations to occur in the child. These cases 
have shown that being homozygous for Marfan-causing FBN1 mutations is likely to be lethal 
before birth and if the child is born they are unlikely to survive more than a few 
months(Capotorti et al., 1959, Chemke et al. 1984, Schollin, Bjarke, & Gustavson, 1988). This 
would seem to point to some phenotypic effect of the unaffected allele. Perhaps some of the 
variation in phenotype is due to level of expression of the unaffected allele. 
 The most prominent symptoms of Marfan syndrome can be found in the skeletal system, 
eyes, and cardiovascular system. This correlates with where elastic fibers are found in the 
greatest abundance in the body. The symptoms affecting the skeletal system are the most visible 
symptoms of Marfan syndrome. Individuals with Marfan syndrome often grow to be taller than 
average and have long and thin arms, legs, and fingers (Loeys et al., 2010). Individuals with 
Marfan syndrome often have highly flexible joints due to the lessened strength and elasticity of 
their ligaments (McKusick, 1991).  
 One of the most common symptoms of Marfan syndrome is poor eyesight. Elastic fibers 
are a large component of the ciliary zonules, which hold the lens in the eye. These fibers suspend 
the lens and connect the lens to muscles which contract and expand to allow the lens to focus 
light on the retina properly. One of the main issues that arises in the eye is that the lens becomes 
dislocated (ectopia lentis) due the weakness of the ciliary zonules. In some cases the dislocation 
is relatively minor and causes nearsightedness due to the lens being shifted closer to the pupil 
and slightly up in the eye. However, the lens can move in any direction and cases of complete 
lens detachment have occurred (Kainulainen et al., 1994).  
 The most serious symptoms of Marfan syndrome are those found in the circulatory 
system, particularly in the aorta. As the primary point of exit for blood from the heart, the aorta 
is very large and flexible as it endures a great deal of pressure. Much of this flexibility in the 
aorta is due to elastic fibers. It is also thought that excess TGF-β causes enlargement of the aorta. 
Those with Marfan syndrome are at high risk for aortic enlargement which can lead to aortic 
dissection (tear in the aorta). Aortic dissection is very serious as it can lead to death very quickly 
and suddenly due to lack of blood supply to other organs, heart failure, or complete aortic rupture 
(Castellano et al., 2013, Jondeau et al., 2011).  
 Due to the discovery of other disorders that share many symptoms with Marfan syndrome 
and the decreasing cost of genetic testing, the diagnostic criteria for Marfan syndrome has been 
revised to place more of an emphasis on the FBN1 gene. The other two other criteria are lens 
dislocation/myopia and aortic root Z-score, which is a measurement taken with an 
electrocardiogram. If the Z score shows an aortic enlargement or possible dissection along with 
an another of the two criteria, the individual is diagnosed with Marfan syndrome (Loeys et al., 
2010, Chubb & Simpson, 2012).  
 As with many dominant disorders, Marfan syndrome presents a more difficult problem. 
In a recessive disorder, typically the disease phenotype is caused by the lack of a certain protein 
or metabolite. However, in the case of Marfan syndrome the disease phenotype is caused by the 
presence of a fibrillin-1 protein that is misfolded and does not function properly. In light of this, 
it has been proposed that an RNA based therapy could be effective in treating Marfan syndrome. 
The goal of such treatment would be to suppress the mutated allele that causes Marfan syndrome 
while allowing the wild-type allele to be expressed (Kilpatrick & Phylactou, 1998). However, as 
the study by Hilhorst et al. (2010) showed, Marfan syndrome could also be caused by 
haploinsuficiency. So, if this is indeed the case, it would seem that down-regulating the mutated 
allele would not be enough to fully treat the disease. To fully treat the disease the wild-type allele 
would have to be up-regulated in order to give the patient the correct gene dosage. 
 Thirty years ago, the life expectancy of those with Marfan syndrome was only 30-40 
years due to problems with diagnosing the disease and lack of treatment options. Though Marfan 
syndrome cannot be cured, there are treatments available today that have increased the life 
expectancy by more than 30 years (Fusar-Poli et al, 2008). One of the most common treatments 
is the use of beta blockers which slow the heart rate and lower blood pressure and decrease stress 
on the aorta. Another promising therapy is the use of angiotensin II receptor antagonists. Not 
only do these antagonists reduce blood pressure, but they also reduce the levels of TGF-β (Keane 
& Pyeritz, 2008). Even with these medications, aortic dissections are possible. If a dissection 
does occur, surgery is generally undertaken to repair the tear with a graft (Castellano et al., 
2013). 
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 Primary Ciliary Dyskinesia (PCD) is a congenital, heterogeneous disease affecting the 
ciliary structure and function [1]. It was first described in 1933, and the cellular basis of PCD 
was described in 1976 [2]. PCD is present in all human races [1], and affects one out of every 
16,000 individuals [3]. PCD is characterized by the immotility or ineffective beating of all cilia 
present in the body [1]. This includes cilia of the upper and lower respiratory tracts, as well as 
spermatozoa flagellae [4]. Situs inversus occurs in 50% of PCD cases. This is due to the inability 
of embryonic cilia to shift the heart to the left side [1]. When situs inversus is present, PCD is 
called Kartagener syndrome [4]. Patients have a 50% chance of developing situs inversus 
because without normal cilia, there is an equal chance of normal and reversed visceral 
transportation [1].  
 PCD is a heterogeneous disease, with many different genes affecting the disease 
phenotype. However, patients in different subgroups of PCD, such as those having different 
morphological defects as caused by different genes, appear to have the same clinical symptoms. 
Physiological effects of PCD can include chronic sinusitis, due to decreased mucociliary 
transport in the paranasal sinuses [1]. This can lead to anosmia [1] and the development of nasal 
polyps [4]. Patients may also develop bronchiectasis by age two or three years, due to inadequate 
mucociliary clearance of the lungs and chronic bronchitis. Because of the inadequate mucociliary 
clearance, the patient must cough to transport secretions within the respiratory tract. PCD 
patients also have a higher risk of otitis, otosalpingitis, and conductive hearing loss due to the 
inadequate mucociliary clearance of the Eustachian tubes and the middle ear. In some cases, an 
IgA deficiency and underdevelopment of the frontal sinuses are also seen in PCD patients. The 
immune system is often normal in examined patients [1]. Daily airway clearance is necessary to 
try to preserve lung function [5]. 
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 There is no formal registry to collect life expectancy data, but most papers say that life 
expectancy of PCD patients is “near normal.” There is also no formal way to assess the average 
age at which disability greatly affects quality of life. PCD has a wide range of symptom severity, 
and therefore may affect patients’ quality of life in varying degrees. There are three general 
periods in which the quality of life of a PCD patient may change. There are often several 
symptoms during the initial diagnosis period, such as chronic lung infections and the need for 
daily airway clearance and treatment with antibiotics. A patient may next experience a 
“Cinderella period” during their adolescence and early childhood. It is named thus, because 
while symptoms are still present, they are often well managed and treatment is required less 
often. Finally, symptoms will become more prevalent and serious after the Cinderella period 
during the third or fourth decade of life. Bronchiectasis that is already present may spread, 
making lung infections more common and severe. Supplemental oxygen may be required, and 
lung transplants may be considered. By the fifth decade of life, many patients report disability 
due to lung impairment [5].  
 PCD has a relatively high prevalence because it is a heterogeneous disease [1]. It affects 
one out of every 16,000 individuals [6], and is present in all human races [1]. The prevalence of 
PCD is relatively high, considering that nearly all males are sterile and females have possibly 
decreased fertility. It is common in parts of Sweden that are isolated or sparsely populated, as 
this region is known as the “inbred island” [1]. PCD is also highly prevalent in two isolated 
populations of Polynesians, however the disease is not associated with Kartagener syndrome in 
this area [4]. 
 It is likely that the inheritance pattern of PCD is an autosomal recessive pattern, as 
determined from pedigrees [1]. One study found that the odds ratio between affected and healthy 
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sibs is close to 1:3 [1]. PCD and Kartagener syndrome have also been observed in monozygotic 
twins, suggesting that Kartagener syndrome is a part of PCD. However, there has not been a 
large-serious study performed to confirm this. The first molecular demonstration of autosomal 
recessive inheritance of lateralization defects was found when it was observed that in some 
patients with PCD, the proper body asymmetry is the result of random determination of left-right 
asymmetry. In two sibships, compound heterozygous mutations resulted in PCD with or without 
left-right inversion. 
It has been difficult for researchers to detect linkage in PCD, as it is a highly 
heterogeneous autosomal recessive condition [4]. Studies can show that the parents of affected 
persons are more likely to be relatives than average [1]. Based on this information, studies have 
been looking into the question of if PCD is a result of a founder’s effect or rather a recurrent 
mutation event. There have also been additional studies looking into alternative inheritance 
patterns for PCD, such as autosomal dominant or X-linked patterns. In one such study, a mother 
had five affected sons with three different fathers, which caused the researched to wonder if 
another inheritance pattern is possible. Because PCD is a heterogeneous disease, it is possible 
that there are different types of inheritance at play that all lead to dynein dysmorphology or 
dysfunction [2]. In general, however, it is accepted that the inheritance pattern of PCD is 
autosomal recessive. 
 PCD is the result of anomalies in the ciliary structure, leading to immotile or ineffective 
cilia. Cilia are made up of nine outer doublet microtubules encircling two inner singlet 
microtubules. This structural bundle is known as the axoneme. The characteristic “9+2” 
microtubule arrangement is seen in a cross section of the axoneme using electron microscopy. 
The axoneme is approximately 0.25 µm in diameter, and can vary in length depending on the cell 
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type and organism. Within the axoneme, inner and outer rows of dynein arms are attached to the 
A tubule of each doublet microtubule, and the dynein arms extend out to the B tubule of the 
neighboring double microtubule [7]. 
Cilia and flagella beat, with bends in the hair-like structures propagating from the 
axoneme base. Ciliary and flagellar movement is due to the sliding between pairs of the outer 
doublet microtubules within the axoneme. The dynein arms are the motor proteins in axonemes 
and are responsible for movement. Formation and breakage of cross-bridges formed between the 
dynein arm and the B tubule, and the binding and hydrolysis of ATP, help produce the force for 
active sliding. Axonemal dyneins are composed up heavy, intermediate, and light chains. The 
heavy chains can hydrolyze ATP, while the intermediate and light chains help secure the dynein 
arm to the A tubule and may help regulate dynein activity. The dynein arms are active at 
different times, based on their location, so that the axoneme can bend in two directions. Actively 
sliding in one half of the axoneme will cause the cilia to bend towards one side, while sliding in 
the other half will produce bending on the opposite side. Through this pattern, the cilia and 
flagella are able to actively beat. Studies have found that the central singlet microtubules and 
radial spokes, which link the central singlets to the A tubules of the outer doublets, may play a 
role in controlling the bend of flagella [7]. 
Variations in the “9+2” pattern, seen in some protozoans, have demonstrated that the 
central singlet microtubules are not necessary for axonemal beating, and that motility is still 
present when there are less than 9 outer doublet microtubules, but with a lower frequency [7].  
There are several genes that may contribute to PCD. The first gene with mutations found 
to be associated with PCD was isolated from Chlamydomonas reinhardtii. Chlamydomonas 
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reinhardtii is an unicellular alga with two flagellum that have similar axonemal structure to 
human respiratory cilia and sperm tails [4]. Loss of function mutations in the human gene related 
to the Chlamydomonas reinhardtii dynein IC78 result in PCD [6]. DNAI1 is also a possible 
contributor to PCD. Axonemal dynein intermediate gene 1 DNAI1 is localized on 9p13-p21 and 
is composed of 20 exons encoding a 699 amino acid protein. Axonemal ultrastructure is highly 
conserved throughout evolution, which indicates that mutations to the genes responsible for this 
structure are not favorable and therefore not selected for. DNAI1 had been found to be 
responsible for some cases of PCD without situs inversus. Compound mutation heterozygosity in 
DNAI1 results in PCD with situs solitus or situs inversus. This may be due to a splicing defect. 
Mutations in DNAH5, a dynein heavy chain gene, have also been associated with PCD. 
Mutations in the dynein heavy chain pseudogene DNAH7p have also been associated with PCD. 
Dynein heavy chains are encoded by multiple genes, and therefore mutations to any of these 
other genes may also play a role in PCD [4]. Mutations in DNAI1 and DNAH5 account for 
almost 30 percent of all PCD cases. Cilia contain over 100 different polypeptides, therefore over 
100 different genes may be involved. In many cases, the exact cause of PCD is unknown. At 
least five types of ciliary defects can be distinguished morphologically, and these defects may 
each have several genetic causes [1]. Transient ciliary abnormalities may also be produced by 
environmental toxins or infections agents. No chromosomal defects have been found as the 
underlying causes of PCD [2]. 
Homologs for the involved genes and proteins have been studied in rhesus monkeys, 
mice, and Drosophila. An example is the iv mice strain kept by Layton, which was used to study 
situs inversus, as well as the hpy mouse mutant, which was used to study male sterility in PCD 
due to sperm immotility [2]. Another study with mouse mutants who were defective in genes 
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required for cilia growth (Hfh4) or beating (Kif3B and Kif3A) demonstrated a link between cilia 
motility and lateralization [4]. 
Many ultrastructural subtypes of PCD seen by electron microscopy, but they all produce 
the same clinical features [1]. PCD and Kartagener syndrome are associated with missing or 
abnormal dynein arms, abnormal radial spokes, and missing central pair of microtubules [4]. 
Disease cilia had absent or abnormally short dynein arms or the spokes were short or absent. A 
reduction in number of dynein arms and in their length was most common abnormality found in 
studies [1]. In some cases of PCD, cilia were also found to have random orientation. In such 
cases, cilia had no ultrastructural defects, but lacked a fixed orientation [1]. 
Diagnostic tests for PCD include examining the ciliary ultrastructure through 
transmission electron microscopy [1], as well as measuring the nitric oxide levels as a screening 
process [5]. Dynein and microtubule structural defects viewed using election microscopy are the 
main diagnostic clues that a patient has PCD. Nitric oxide levels are chronically reduced in PCD. 
This is notable because nitric oxide production is upregulated in the respiratory epithelium 
during infection. Therefore, it would be expected for an individual with chronic lung infections 
to have elevated nitric oxide levels. If the levels are actually reduced, it is a sign that the patient 
may have PCD. Chest x-rays may also be used to diagnose PCD [5]. 
The major challenges for patients with PCD include maintaining air way clearance, and 
living with chronic upper and lower respiratory infections and chronic otitis media. Currently, 
efforts are focused in treatments that slow the progression of the disease and help manage 
symptoms. In order to monitor airway health, sputum cultures may be studied, and pulmonary 
function tests, imaging, and bronchoscopies may be performed. These procedures may be done 
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during a period of patient health to provide a “baseline” for later comparison. It is recommended 
that routine sputum cultures are taken every six to twelve months, as well as during infection. 
Pulmonary function tests have been historically used for patients with cystic fibrosis, asthma, 
and chronic obstructive pulmonary disease. Studies are not clear on the value of pulmonary 
function tests in patients with PCD, but it is still recommended patients have these tests every 
three to six months. Baseline CT scans are important when looking for structural changes of the 
lungs, such as the presence and progression of bronchiectasis. CT scans should be limited, 
however, due to the radiation exposure. X-rays can also be useful when looking for pneumonia, 
but it is more difficult to see structural changes, like bronchiectasis, on an x-ray. Bronchoscopy 
allows for the physician to look directly into the passageways of the patients’ lungs, as well as 
for the removal of mucus plugs or collecting tissue samples [5]. 
The most important thing for patients with PCD to do is to maintain airway clearance. 
This helps preserve lung function, as well as prevent future infections. This can be done through 
chest physiotherapy, vest therapy, acapella, flutter, or quake devices, mucus-thinning drugs, 
bronchodilators, antibiotics and steroids. Chest physiotherapy and vest therapy are also used for 
cystic fibrosis patients and they both work to physically loosen and move mucus secretions out 
of the lungs and the airway. Acapella, flutter, and quake devices are positive expiratory pressure 
devices, and help open up the airways, and in some cases vibrate the airways, in order to help the 
patient cough mucus up an out of the respiratory system. Physical exercise also helps to open up 
the airways and move mucus out of the lungs. Mucus thinning drugs help thin secretions in order 
to make them easier to remove. Bronchodilators act to open and relax the airways, which helps to 
move mucus out. Antibiotics and steroids can be used on a case-by-case basis to treat infection, 
or as a preventative measure. Myringotomy tubes and hearing aids may also be necessary when 
8 
	
chronic otitis media is present. Usually a combination of these physical and pharmaceutical 
treatments is used to treat PCD [5]. 
Further research into the mechanism and treatment of PCD is supported by NID-
sponsored Genetic Disorders of Mucociliary Clearance Consortium (CGMCC). The clinical 
studies available are focused on understanding PCD rather than trying gene therapies. Currently, 
clinical studies include comparing the inflammatory and microbiologic marker in sputum in 
cystic fibrosis and PCD patients, studying the long-term lung function and disease progression in 
children with early onset PCD, studying pathogens of PCD lung disease, and studying 
dyskinesia, heterotaxy, and congenital heart disease [5]. Advocacy groups for patients with PCD 
include the PCD Foundation [5] in North America and the PCD Family Support Group [8] in the 
United Kingdom.  
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 	 Parkinson’s	disease	(PD)	is	a	nervous	system	progressive	disorder	due	to	basal	ganglia	degeneration	and	a	decrease	of	dopamine	[1].	PD	is	the	second	most	frequent	neuro-degenerative	disease	behind	Alzheimer’s	disease,	since	it	occurs	more	than	1%	after	the	age	of	65	years	[2].	There	are	many	similarities	and	differences	between	these	two	diseases,	which	will	be	covered	later.	PD	is	found	in	1	million	people	in	the	US,	while	60,000	people	are	diagnosed	every	year	(US)	and	4	million	people	worldwide	[3].	The	demographic	breakdown	of	the	disease	is	as	follows:	PD	occurs	in	about	1-2%	of	people	at	age	60,	1	million	in	the	US,	and	4	million	worldwide	[3];	PD	affects	1.7%	of	the	Chinese	population	[4];	60,000	people	get	diagnosed	every	year	in	the	US	with	PD	[3].	It	is	inherited	and	usually	has	two	possible	ways	of	inheritance.	PD	follows	an	autosomal	dominant	or	autosomal	recessive	inheritance	pattern,	depending	on	what	gene(s)	are	affected	[2].		So,	with	the	frequency	of	this	disease,	what	causes	PD?		 James	Parkinson	discovered	the	disease	in	1817	[1].	Parkinson’s	relies	on	the	mechanisms	and	pathways	of	neurotransmitters.	The	neurotransmitter	dopamine	is	defected	or	at	abnormal	levels	in	a	patient	that	suffers	form	PD.	Torquato	Torqauti	first	isolated	dopamine	in	1910	[1].	The	discovery	of	the	disease	coupled	with	the	discovery	of	neurotransmitters,	especially	dopamine	greatly	helped	the	further	studies	on	PD	and	how	it	works.	The	discovery	of	Neurotransmitters	paved	the	way	for	further	PD	studies.		 PD	is	often	caused	by	genetic	predisposition	and	exposure	to	certain	toxins	such	as	chronic	exposure	to	herbicides	and	pesticides	may	cause	mutations	in	PD	causing	genes	[5].	These	chemicals	cause	a	disruption	in	genes	by	entering	the	genome.	These	genes	code	
for	proteins	that	produce	neurotransmitters.	The	brain	ages	slow	and	progresses	slowly,	which	will	result	in	defective	cognitive,	memory,	and	motor	functions,	so	aging	is	a	major	factor	for	PD	[6].	During	aging,	increases	in	metabolic	or	oxidative	stress	can	lead	to	neuronal	defects	and	cell	death	[6].																	Dopamine	is	affected	in	patients	that	suffer	from	PD.	This	is	due	to	defects	in	genes	where	proteins	cannot	produce	enough	dopamine.	A	major	effect	of	PD	is	that	it	leads	to	a	loss	of	neural	transmitters,	which	ultimately	causes	loss	of	motor	control.	Parkinson’s	disease	(PD)	mainly	affects	middle	aged	or	elderly	people	[1].	This	is	due	to	“wear	and	tear”	on	the	body;	PD	can	arise	in	all	ages,	however	this	is	usually	rare.	Common	Symptoms	of	PD	include	tremor,	dyskinesia,	rigid	muscles,	as	well	as	less	accurate	movement	or	muscles	[3].	The	disease	is	progressive,	is	often	times	not	fatal	but	PD	gets	worse	over	time	[3].	The	saying	with	PD	is		“you	will	die	with	Parkinson’s,	not	from	it	[3]”.	Essentially	PD	does	not	harm	your	organs	just	the	response	of	the	nervous	system	and	it’s	ability	to	send	neurotransmitters.	There	are	medical	options	that	help	control	your	body	by	helping	the	body	cope	with	the	defect,	but	as	of	now	PD	has	no	cure.	A	big	foundation	to	finding	a	cure	is	the	Michael	J.	Fox	foundation.		He	is	a	celebrity	that	suffers	from	PD	and	he	greatly	supports	the	research	to	help	patients.	The	National	Institute	of	Neurological	Disorders	and	Stroke	(NINDS)	is	also	researching	new	cures	and	coping	mechanisms	for	PD.	What	genes	or	mutations	are	these	research	institutes	looking	at?		 The	first	identified	mutation	in	PD	was	a	missense	mutation	of	A53T	in	alpha	synuclein	gene	[7].		PD	commonly	results	from	a	mutation	in	LRRK2,	PARK2,	PINK1,	PARK7	and	the	SNCA	gene	[3].	The	most	common	genes	affected	are	PARK1,	PARK2	and	PARK7	genes	[3].	The	gene	PARK1	associated	with	PD	was	first	linked	to	PD	in	1995	[5].		PARK1	is	
located	on	chromosome	4	and	codes	for	alpha	synuclein	[5].	PARK	2	is	located	on	chromosome	6	and	codes	for	the	protein	parkin	[5].	PARK7	is	found	on	chromosome	1	and	codes	for	protein	deglycase	or	DJ-1	[5].	This	finding	led	to	other	studies	to	see	how	gene	defects	leads	to	defective	proteins	such	as	parkin	and	how	it	decreases	dopamine,	which	is	needed	for	motor	skills.		 Although	there	are	mutations	in	some	genes,	a	person	with	PD	does	not	have	a	different	karyotype	than	a	normal	person	[5].	A	patient	with	PD	will	have	23	chromosomes,	however,	it	may	be	missing	parts	or	segments	of	chromosomes,	some	could	be	noticeable,	whereas	some	are	not.	Gross	chromosomal	rearrangements	may	also	lead	to	deletions	or	defective	genes	that	can	cause	PD.	Mutations	in	the	PARK2	and	PARK7	genes	are	the	most	frequent	mutations	for	people	with	PD	[5].	PARK2	encodes	parkin,	which	is	found	in	the	mitochondria	[5].		Parkin	helps	degrade	unneeded	proteins	by	tagging	proteins	that	are	damaged	or	in	excess	and	help	maintain	mitochondria	[5].	Parkin	is	expressed	in	the	brain	or	substantia	nigra	[5].	Parkin	is	a	vital	protein	coded	by	the	PARK	genes.	PARK7	encodes	a	protein	of	the	peptidase	C56	family	[5].	PARK	mutations	occur	worldwide	in	diverse	ethnic	groups	[5].		 		 There	are	many	mutations	that	lead	to	a	defect	in	PARK	genes.	PD	causing	genes	such	as	PARK2	could	be	deleted,	duplicated	or	contain	a	mutation	that	codes	for	a	different	amino	acid	(missense)	[3].	A	different	coding	sequence	leads	to	defective	genes	and	proteins	that	affect	the	nervous	system	and	the	cells	that	make	up	this	system.	A	mutation	will	kill	cells	which	lead	to	no	dopamine	production.	This	leads	to	a	severe	decrease	in	Dopamine.	
	 The	main	cells	affected	are	neurons	and	the	nervous	system,	which	cause	a	defect	in	the	ubiquitin-proteasome	system	as	well	as	a	loss	of	function	of	parkin	that	cannot	control	the	release	of	dopamine,	which	is	needed	for	control	of	muscles	[5].	Parkin	is	a	46	amino	acid	long	protein	located	at	the	PARK	2	locus	on	the	long	arm	of	chromosome	six	[8].	Parkin	functions	as	an	ubiquitin	ligase	that	will	attach	ubiquitin	molecules	to	wrongly	folded	proteins	to	flag	them	so	they	can	be	processed	by	the	proteasome	[8].	Parkin	targets	damaged	proteins	and	degrades	them	to	regulate	the	release	of	dopamine	[5].	Parkin	is	found	in	the	ubiquitin-proteasome	pathway	that	degrades	proteins,	and	without	this	function	it	is	lethal	to	cells	[5].	Parkin	kills	damaged	cells	and	is	how	the	body	reacts	to	the	damaged	cells.	Therefore	if	parkin	cannot	degrade	defective	proteins,	the	cells	will	have	degraded	proteins	that	will	not	be	able	to	produce	proteins,	which	ultimately	leads	to	cell	death.	PD	patients	are	able	to	survive	because	they	still	produce	some	dopamine	which	allows	them	to	move,	however	it	may	be	uncontrollable.		 		 Mutations	in	PARK2	lead	to	degradation	and	cell	death	of	the	substantia	nigra	[5].	Nerve	cells	in	this	region	produce	dopamine,	and	this	tissue	death	leads	to	an	inability	to	produce	dopamine	[9].	Nerve	cells	produce	dopamine	by	signaling	molecules	at	junction	gap	receptors	[9].	These	receptors	produce	action	potentials	that	release	dopamine	[9].	Loss	of	PARKIN	function	leads	to	abnormal	mitochondrial	structure	and	function	[10].	Mitochondria	functions	in	energy	production	and	is	vital	to	powering	protein	productions	that	are	used	in	all	cells	[10].	Dopamine	relays	messages	that	control	body	movement,	and	a	lack	of	dopamine	severely	hurts	this	ability	[1].	The	actual	phenotype	depends	on	what	gene	is	affected	in	one’s	genome.	Different	mutations	can	lead	to	different	symptoms	and	
defective	proteins	based	on	what	gene	is	affected	[8].	Heterozygous	patients	with	PD	experience	less	sever	symptoms	than	those	with	homozygous	mutations	of	PD	genes	[8].	The	neurons	cannot	create	action	potentials	to	stimulate	the	nervous	system	to	control	motor	movements.	The	most	noticeable	phenotype	is	uncontrollable	shaking	and	posture	instability	due	to	loss	of	motor	skills.	Another	symptom	is	the	reduced	ability	to	swallow	since	neurons	power	muscles	needed	to	swallow.	Dopamine	is	a	very	important	physiological	role	controlled	by	parkin	and	is	conserved	in	mammalian	genetics	[1].		Since	this	gene	is	vital	to	mammals,	various	animal	models	can	look	at	genes	at	a	more	in	depth	level	with	manipulation	and	other	variables.				 In	order	to	research	this	disease	mouse	models	are	frequently	used	to	study	PD	because	of	the	similarity	of	PD	with	other	neuro-degenerative	diseases	such	as	Alzheimer’s	[3].	It	is	crucial	to	see	the	differences	between	the	two	diseases.	Alzheimer’s	has	very	similar	symptoms	because	it	is	a	neurodegenerative	disease	and	is	a	result	of	the	aging	process	and	accumulation	of	mutations	[8].		Alzheimer’s	is	a	disease	that	results	from	gene	defects	that	are	important	in	a	different	part	of	the	brain,	the	hippocampus	and	the	entorhinal	cortex	[8].	Dopamine	is	not	able	to	transfer	messages	from	this	part	of	the	brain,	which	often	results	in	memory	loss	and	not	motor	loss,	due	to	the	nature	of	the	hippocampus	[1].	Since	these	two	diseases	are	very	correlated,	different	animal	models	are	used	to	study	PD.	Mice	are	widely	used	as	an	animal	model	for	researching	PD	[6].	To	do	this,	mice	are	injected	with	toxic	chemicals	that	cause	loss	of	function	in	PD	causing	genes	such	as	the	SNpc	region	[6].	Motor	function	decreases	in	mice	as	they	age	[6].	Age	associates	genes	that	most	affected	mice	can	be	used	to	look	at	in	humans	with	PD	[6].	Age	
associated	genes	are	prone	to	mutations	because	they	have	an	accumulation	of	mutations	over	time,	not	because	of	the	age	itself.	From	the	in	depth	study	on	mice	models,	newer	treatments	could	arise	to	help	patients	cope	with	PD.	Mice	are	also	used	because	in	mice	the	substantia	nigra	also	degenerates	due	to	mutations	in	PARK2	and	PARK7	[1].	The	model	is	that	mice	will	get	injected	to	decrease	dopamine	production	and	degrade	the	substantia	nigra	so	that	it	resembles	a	human	that	suffers	from	PD.		 		 The	diagnostic	test	used	to	see	if	someone	as	PD	is	a	neurological	examination	performed	by	the	doctor	as	well	as	medical	history	examination	[2].	Family	history	and	family	trees	is	a	very	good	indicator	of	PD.	It	can	give	you	a	probability	of	inheriting	the	disease	and	can	help	determine	if	your	kids	are	at	risk	as	well.	This	is	vital	since	it	has	inheritance	patterns	as	stated	previously.	This	is	commonly	used	to	diagnose	people	to	see	if	they	have	PD	or	not.		PD	can	be	predicted	to	see	a	child’s	risk	or	can	be	used	to	see	a	patient’s	likelihood	of	contracting	the	disease.	Through	medical	history	examination	and	a	neurological	test,	PD	can	be	detected	[8].	Stem	cells	in	embryos	can	be	directed	to	make	more	dopamine,	which	can	help	avoid	PD	before	birth	[8].	However	this	has	to	be	done	at	a	very	early	age,	and	even	in	the	womb,	but	sometimes	it	is	hard	to	detect	PD	in	a	baby	before	birth.	Most	of	the	stem	cell	research	is	proposed	and	is	not	being	used	because	of	the	ethical	dilemma.	There	are	several	treatments	and	drugs	used	to	help	cope	with	PD.													Carbidopa-levodopa	is	the	most	effective	medication	since	it	is	a	natural	chemical	that	can	enter	the	brain	since	it	can	pass	through	the	blood	brain	barrier	[5].	This	drug	is	effective	because	it	can	be	converted	to	dopamine	to	help	increase	dopamine	levels	in	the	body	[5].	By	having	a	drug	that	can	be	turned	into	dopamine	will	greatly	help.	Another	
effective	drug	is	called	a	MAO-B	inhibitor.	MAO-B	inhibitors	help	prevent	the	breakdown	of	the	brain	dopamine	by	inhibiting	enzyme	monoamine	oxidase	B,	which	metabolizes	dopamine	[5].	This	will	allow	dopamine	to	buildup	and	not	be	degraded,	which	can	help	increase	levels	of	dopamine	in	the	brain.	Another	great	treatment,	although	controversial	is	Deep	Brain	Stimulation	(DBS)	can	help	stimulate	parts	of	the	brain	that	are	used	to	control	motor	movement	and	help	activate	parts	of	the	brain	that	are	not	frequently	activated	due	to	defective	genes	[11].	It	is	controversial	because	many	people	think	deep	brain	stimulation	can	be	harmful	to	normal	individuals.	However,	it	is	being	tested	further	and	will	hopefully	improve	life	of	those	suffering	with	PD.			 S											Parkinson’s	Disease	has	no	cure	and	most	of	the	problems	are	due	to	defective	genes	that	cannot	code	for	the	parkin	protein	that	get’s	rid	of	damaged	proteins	that	make	dopamine.	Most	treatments	attack	the	problem	of	low	levels	of	dopamine	in	the	body	and	find	different	ways	to	increase	dopamine	in	the	brain.	Medical	treatments	to	help	control	muscles	by	dopaminergic	therapy	can	help	improve	quality	of	life	[8].	Dopaminergic	therapy	is	adding	in	dopamine	neurotransmitters	to	the	right	tissues	in	the	brain.	Since	there	are	no	cures,	therapy	to	help	patients	cope	with	PD	can	help	patients	live	a	longer	life.	This	is	crucial	because	there	are	millions	of	people	in	the	US	and	around	the	world	that	suffer	from	PD.		Future	studies	and	advancement	in	technology	to	identify	more	pathways	associated	with	PD	will	greatly	improve	the	chances	of	curing	PD.	As	for	now,	only	treatments	can	help	cope	with	PD.		If	further	studies	can	find	how	to	fix	gene	defects	so	that	they	can	produce	the	correct	amino	acid	sequence	in	order	to	produce	parkin	proteins,	
dopamine	levels	will	rise.	However,	the	complex	nature	of	the	pathways	coupled	with	the	genome	will	create	big	challenges	in	order	to	cure	this	disease.			 	 P		 Parkinson	
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Introduction	to	Werner	Syndrome	
	 Werner	Syndrome	(WS)	is	one	of	the	segmental	progeroid	syndromes	diseases	manifesting	accelerated	aging	that	affect	multiple	organs	and	tissues	(Martin	and	Oshima	2000).	The	disease	is	named	after	the	German	scientist,	Otto	Werner	who	discovered	and	identified	the	syndrome	from	four	siblings	who	had	the	symptom	of	premature	aging	in	1904.	WS	was	discovered	to	result	from	rare	autosomal	recessive	alleles	of	mutations	at	the	WRN	gene	on	chromosome	8,	which	encodes	the	RecQ	DNA	helicase	(Yu	et	al.	1996).	There	is	also	the	known	chance	that	the	disease	mutations	tend	to	run	in	families.	Both	sexes	can	be	affected	and	also	with	even	higher	change	between	brother	and	sisters	from	the	same	carrier	or	infected	parents	since	(Takemoto	et	al.	2013).		 The	global	incidence	rate	of	Werner	Syndrome	disease	is	less	than	1	in	100,000	live	births	(Hasty	et	al.	2003).	However,	in	Japan	and	Sardinia,	they	tend	to	have	a	higher	rate	of	1	in	20,000-40,000	and	1in	50,000,	respectively	(Masala	et	al.	2007).	The	approximate	Lifespan	for	these	WS	patients	is	around	50	years	old	globally	(Hasty	et	al.	2003),	47-48	in	Japan,	and	54	years	in	Sardinia	(Masala	et	al.	2007).		 In	between	2009-2011,	a	nationwide	epidemiology	study	in	Japan	was	conducted	with	6921	surveys	sent	to	hospitals	and	clinics	experienced	with	WS	(Takemoto	et	al.	2013).	They	found	that	more	than	90%	incidence	were	recorded	as	cardinal	signs,	symptoms	or	sign	of	heart	disease,	with	many	criteria.	WS	patients	are	usually	observed	as	having	a	normal	phenotype	early	in	life	until	they	reach	the	late	20s	to	early	30s,	where	the	first	symptoms	begin.	The	first	clinical	sign	of	WS	is	
a	lack	of	early	adolescent	growth	spurt,	which	leads	to	short	stature,	loss	of	body	weight,	skin	atrophy,	Loss	of	regional	subcutaneous	fat,	and	graying	of	hair.	The	loss	of	fat	is	usually	related	to	the	ulcerations	in	the	regions	such	as	elbows	and	ankles.	In	addition,	the	limb	ulcers	are	influenced	by	neuropathy	and	vascular	insufficiency,	which	may	require	amputation	later	on.	Others	symptoms	include	type	2	diabetes	mellitus,	osteoporosis,	bilateral	ocular	cataracts,	several	forms	of	arteriosclerosis,	alopecia,	malignancies,	telangiectasia,	and	peripheral	neuropathy	(Leistritz	et	al.	2007).		 The	severity	of	patients	with	Werner	syndromes	can	be	explained	by	the	different	functions	of	WRN	gene,	which	plays	a	very	important	role	in	DNA	replication,	repair,	and	recombination.	One	WS	characteristic	is	increasing	genomic	instability	due	to	many	mutations,	which	likely	is	the	cause	of	cancer	and	many	more	disease	that	normally	have	a	late	onset	in	unaffected	individuals	(Crabbe	et	al.	2007).	However,	the	common	cause	of	death	among	WS	patients	is	usually	related	to	myocardial	infarction	or	cancers	(Huang	et	al.	2006).		
Genetic	component	of	the	disease	
	 After	the	discovery	of	the	Werner	Syndrome	in	1904	as	part	of	Otto	Werner’s	dissertation	research	in	Germany,	many	researchers	and	geneticists	have	been	both	accidently	and	directly	identified	the	WRN	gene	and	its	relative	functions	leading	to	the	diseases	and	the	different	phenotypes	between	affected	individuals.	Later	in	1934	to	1941,	two	scientists	from	New	York,	Oppenheimer	and	Kugel,	named	the	term	“Werner	Syndrome”	igniting	the	popularity	on	this	research	topic.	However,	it	
was	not	until	1981	that	the	real	genetic	component,	the	WRN	gene	on	chromosome	8,	was	discovered	for	the	first	time	after	centuries	of	study	by	many	geneticists	(Goto	2004).		 Werner	Syndrome	is	caused	by	mutation	of	the	WRN	gene	on	chromosome	8.	The	approximate	size	of	this	gene	is	250	kb,	containing	about	35	exons,	34	of	which	are	protein	coding	(Yu	et	al.	1996).	The	WRN	protein	is	a	180-kb	multifunctional	nuclear	protein	that	belongs	to	the	RecQ	family	of	helicases	(Grey	et	al.	1997).	Among	WS	affected	individuals,	their	karyotypes	usually	differ	from	the	normal	population	karyotype	due	to	the	abnormal	expression	of	the	mutated	WRN	gene.	This	difference	in	WRN	expression	can	cause	the	loss	of	a	telomere	at	the	end	of	chromosome,	which	can	consequently	create	fusions	between	chromosomes	or	sister	chromatids,	reciprocal	translocations,	leading	to	a	change	in	karyotype	(Crabbe	et	al.	2007).		 One	main	role	of	WRN	requires	an	N-terminal	domain	that	codes	for	exonuclease	activity	(Huang	et	al.	1998)	and	also	where	a	domain	for	single	strand-DNA	annealing	activity	is	happened	to	be	located	(Muftuoglu	et	al.	2008).	Within	this		N-terminal	domain	with	single	strand-DNA	annealing	activity	of	helicase	and	exonuclease,	the	main	wild	type	functions	are	thought	to	be	related	to	DNA	repair,	DNA	recombination,	and	DNA	replication	of	the	chromosome	(Brosh	et	al.	2006;	Friedrich	et	al.	2010).	Furthermore,	the	proteins	produced	from	WRN	gene	are	also	involved	in	telomere	maintenance	(Crabbe	et	al.	2007).		 The	mutations	in	WRN	create	malfunction	or	absence	of	the	proteins.	There	are	more	than	70	WRN	gene	mutations	found	in	human,	such	as	nonsense	
mutations,	missense	mutation,	substitutions	at	splice	junction,	and	insertion/deletions	have	been	showed	in	WS	patients	(Aydogan	et	al.	2015).	These	different	in	mutations	however	are	possible	to	cause	some	slightly	different	in	the	disease	symptom.		
Molecular	biology	and	biochemistry	of	the	disease	
	 Study	of	Laure	Crabbe	in	2006	has	proven	that	the	cause	of	genomic	instability	in	WS	cells	has	the	direct	effect	on	the	telomere	dysfunction.	Since	human	linear	chromosomes	undergo	terminal	sequence	loss	during	cell	replication	and	eventually	the	telomere	become	critically	short	(Crabbe	et	al.	2007).	This	is	one	important	concept	because	one	of	telomere	main	function	is	to	maintain	the	chromosome	stability.	Abnormalities	phenotype	or	shortening	of	the	telomere	region	on	the	chromosome	may	eventually	leads	to	complication	like	chromosomal	breakage	and	translocation	(Friedrich	et	al.	2010).			 The	phenotype	of	the	disease	at	the	cellular	level	is	usually	observed	by	visualizing	the	telomere	region,	repeated	sequences	at	both	ends	of	the	chromosomes.	Since	the	mutation	in	the	WRN	gene	is	proven	to	have	the	direct	affect	on	shortening	the	telomere	on	the	chromosomes,	different	phenotypes	at	the	cellular	may	be	able	to	identify.	Among	these	differences,	the	chromosome	breakage	and	translocation	of	chromosomes,	rejoined	region	of	two	different	chromosomes	may	be	able	to	visualized	in	the	karyotype	as	well	(Friedrich	et	al.	2010).			 There	are	many	cell	types	and	tissues	involved	with	the	Werner	Syndrome.	Because	of	the	mutations	within	the	WRN	gene	that	is	normally	function	as	the	
growing	stimulator	and	telomere	maintaining	mechanism.	Mutations	in	WRN	gene	then	is	possible	to	interrupt	the	normal	function	of	the	gene,	causing	the	change	in	different	types	of	protein	productions,	which	leads	to	the	abnormal	development	of	the	effected	cells	and	tissues.	These	cells	and	tissues	abnormalities	tend	to	manifest	the	old	person	age	phenotype,	which	again	leads	from	the	malfunction	of	the	proteins	produced	from	the	mutant	WRN	gene.	Many	obvious	examples	are	greying	of	hair	color	from	the	effected	hair	cells,	and	early	ulcerations	of	the	skin	from	the	effected	skin	cells	and	tissues.			 The	WRN	proteins	involve	with	helicase	and	exonuclease	activity	(Yu	et	al.	1996).	The	main	function	of	the	Werner	protein	produced	from	WRN	gene	is	required	for	cell	growth	and	proliferation	(Li	et	al.	2014).	The	cellular	pathways	involved	WRN	protein	that	has	been	studied	implied	that	it	monitor	and	maintain	DNA	integrity	(Rossi	et	al.	2010).	Other	known	tasks	of	this	protein	are	maintenance	and	DNA	repair.	The	protein	also	supports	the	process	of	DNA	replication	as	a	preparation	for	cell	division.		 Mutations	in	the	WRN	gene	lead	to	the	production	of	an	abnormally	short	and	nonfunctional	WRN	protein.	This	protein	is	also	believed	to	broken	down	very	easy	and	unable	to	transport	to	the	cell’s	nucleus,	where	it	normally	interact	with	DNA.	However,	we	are	not	yet	fully	understood	how	the	mutations	in	WRN	gene	lead	to	WS	signs	and	symptoms.	One	assumption	would	be	that	cells	with	mutant	WRN	protein	tend	to	divide	more	slowly	and	stop	dividing	earlier	compared	to	the	normal	cells,	which	affect	growing	process	of	the	individuals	carrying	the	disease.	In	addition,	the	nonfunctional	WRN	protein	also	allows	the	DNA	damage	to	increase,	
which	disrupts	the	normal	cells	functions	and	the	cells	will	usually	be	associated	with	diseases,	cancers	(Aggarwal	et	al.	2011).		 The	WRN	gene	also	found	to	be	highly	conserved	within	mice	population.	Many	scientists	discovered	known	homolog	of	the	proteins	in	mice	and	also	the	mutation	is	in	a	conserved	in	the	region	of	WRN	gene	in	mice	(Li	et	al.	2014).	The	study	shows	that	the	mutations	in	the	mouse	WRN	gene	also	cause	the	early	death	and	many	complication	age-related	disorders,	similarly	to	human.			
Clinical	aspects	and	organismal	phenotypes	
	 The	most	popular	diagnostic	test	for	Werner	is	the	Next-generation	sequencing	analysis	of	the	WRN	gene,	looking	for	the	WRN	mutations,	especially	Frame	shift	mutation	(Yang	et	al.	2015).	However,	there	are	different	levels	of	the	diagnostic	options.	For	example,	the	level	of	biochemical	genetic	test	likes	protein	analysis.	Another	level	is	molecular	genetics	tests,	which	is	for	mutations	like	deletion/duplication	analysis,	and	sequencing	analysis	of	the	entire	coding	region	is	also	fall	into	this	group	of	diagnostic.			 Variability	in	phenotype	of	WS	is	highly	a	penetrant	gene	at	least	for	disease	like	cancer	(Yang	et	al.	2015).	Many	individuals	could	become	a	carrier	that	the	disease	alleles	are	penetrant.	However,	WS	phenotype	could	be	extremely	expressivity	when	the	individuals	carry	two	mutant	alleles	in	the	WRN	gene,	which	lead	to	the	manifestation	of	the	normal	aging-related	diseases.		 Role	of	the	genetic	element	in	other	disease	like	cancer	is	very	well	studying	right	now.	According	to	the	Liu	Yang	study	in	2015	identified	that	novel	WRN	
frameshift	mutation	was	identified	in	three	cancer	patients	and	one	in	the	youngest	unaffected	daughter,	carrier.	In	the	other	disease	involving	cardinal	muscle	is	also	highly	possible	to	be	affected	by	the	genetic	element	abnormalities	of	the	WS.		 	
Issues	for	the	affected	individual	and	treatments	prospects	
	 To	detect	the	disease	early	on,	the	family	members	of	the	infected	individual	with	the	Werner	Syndrome	are	required	to	have	the	sequencing	analysis	tested	for	the	mutant	WRN	gene.	The	couples	consulting	for	sequencing	analysis	test	before	having	children	can	also	be	performed	to	avoid	having	the	infected	children	with	the	WS.		 		 Many	treatments	or	technics	for	several	symptoms	of	Werner	Syndrome	have	found	to	be	very	effective.	For	example,	treatment	for	skin	ulcers	with	standard	or	novel	techniques	is	proven	to	help	reducing	the	causative	of	the	symptom	(Yeong	&	Yang	2004).	Another	treatment	option	for	skin	ulcers	is	the	Bosentan,	digital	ulcers	treatment,	which	it	is	proven	to	be	very	effective	in	people	with	Werner	syndrome	having	complication	with	the	skin	ulcers	(Matucci-Cerinic	et	al	2011).	Scanning	for	type	2	diabetes	mellitus	and	consulting	with	the	physician	for	controlling	the	symptom	may	also	help.	Acceptable	results	have	been	reported	with	use	of	pioglitazone	to	treat	for	the	insulin	resistance	in-patient	with	WS	(Imano	et	al	1997).	Regular	treatment	for	malignancies	in	WS	is	also	one	of	the	options	to	treat	for	tumors	and	cancer	related	symptoms.			 The	major	challenges	faced	by	individuals	with	the	disease	is	always	involving	maintaining	the	healthy	conditions,	since	many	abnormalities	both	
genotype	and	phenotype	of	the	infected	individuals	are	constantly	increase	overtime.	Since	it	is	very	difficult	to	treat	or	reduce	the	symptoms	of	the	WS.	Individuals	could	prevent	secondary	complications	by	adjusting	their	Lifestyle.	For	example,	smoking	avoidance,	regular	exercise,	and	weight	control	to	reduce	atherosclerosis	risk	are	extremely	recommended	by	the	physicians.	Excellent	skin	care,	trauma	avoidance,	and	examination	to	treat	problems	early	may	also	help.		 	
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Sickle Cell Disease 
 
The foundation of sickle cell disease is built on the β-globin variant found on the short 
arm of chromosome 11 [1]. Hemoglobin composition changes throughout development. Fetal 
hemoglobin (HbF) is composed of two α-globin proteins and two γ-globin protein [2]. Adult 
hemoglobin (HbA) will have two β-globin proteins adjoining two α-globin proteins [1,2]. At 
birth, the infant has roughly 80% HbF and 20% HbA. This transition is complete around 6 
months with HbA being the homozygous dominant, or wild-type [2]. Deformity of red blood 
cells into a crescent-shape is due to variation in the β-globin amino acid chain. At position 6, 
valine replaces glutamic acid causing the polymerization of deoxy sickle hemoglobin (HbS). 
This leads to the formation of long protein chains causing complications such as vasoocclusion 
and hemolytic anemia [1,3].  
With this disease, those that are homozygous for wild-type alleles (HbA) are completely 
unaffected while those that are homozygous recessive typically suffer from anemic disorders. 
Recessive homozygosity can result from two copies of HbS or one copy of HbS and another β-
globin variant such as HbC, HbE, and HbD [1,3]. In addition, recessive variations include α 
thalassemia and β thalassemia [3]. Thalassemia is a Greek word referring to autosomal 
inheritance of blood disorders. Alpha-thalassemia results from a mutation on chromosome 16 
causing a deficiency in α-globin proteins which in turn produces excess β-globin proteins. 
Because this mutation occurs on different chromosome, another gene separate from the one for 
sickle cell disease, it does not affect the genotype. However, it has shown to have phenotypic 
implications [4]. Beta-thalassemia is caused by the deficiency of β-globin proteins leading to 
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additional α-proteins, and the mutation is found on chromosome 11 [2]. Beta-thalassemia 
mutations are also allelic variations of the globin genes that can be passed on to the offspring [1]. 
There are two types of β-thalassemia, β0 and β+. Both cause a reduction in β-globin; however, β0 
causes complete absence of hemoglobin synthesis leaving those individuals with phenotype 
produced by the other copy present [2]. If they are HbS/ β0 thalassemia, they would be 
phenotypically similar to those that are HbS/HbS. Most patients with β+ have shown milder 
forms of the disease as it still produces some normal hemoglobin [3]. 
Heterozygous individuals are often unaffected by the downfalls of the disease, but 
maintain an additional beneficial aspect not seen in wild-type individuals. Heterozygosity has 
benefits through conferring resistance to malaria without the harmful side effects [3]. This is due 
to production of HbS from only one allele. Because the other allele for heterozygotes (HbA) 
produces normal hemoglobin, the symptoms such as vasooclusion and anemia to not develop, yet 
these individuals are still protected from malaria [1,3].  Resistance to human malaria was first 
genetically demonstrated in 1954 when sickle-cell heterozygous individuals responded 
significantly less to Plasmodium falciparum infections [4]. Continued research including 
genome-wide associations has identified the HBB locus to be the source of this resistance. 
Populations living near the coasts Kenya and Lake Victoria have higher frequencies of sickle-
cell heterozygotes than those in the highlands where malaria is uncommonly transmitted [4]. 
This follows the concept of positive selection. In populations living in areas where malaria is 
high, there has been a genetic shift toward an increase in heterozygotes because these individuals 
show greater fitness. This explains the absence of a selective sweep involving the removal of the 
sickle cell allele. This is supported by studies of P. falciparum transmission into individuals, 
(HbA/HbS, HbA/HbA, HbS/HbS). Sickle-cell heterozygotes (HbA/HbS) survive better than 
Phillips 3 
	
	
those with normal hemoglobin, homozygous dominant (HbA/HbA) [4]. Homozygous recessive 
(HbS/HbS) have the highest mortality rate due to the symptoms of the deformed red blood cells.  
The carrier form of HbS has been found to be negatively associated with all potentially 
lethal forms of falciparum malaria; however, HbC and α-thalassemia have not shown protection 
against malaria and are limited to conditions of cerebral malaria and severe anemia, respectively 
[4]. HbS red blood cells are assumed to have specific physical or biochemical properties which 
affect the invasion, growth, and development of P. falciparum parasites. [5].When such cells 
undergo in vitro, parasite-infected HbA/HbS red blood cells also tend to sickle. In Sudan, the 
immune system’s recognition of P. falciparum infected red blood cells was greater in children in 
addition to the up-regulation of malaria-specific cell-mediated immune responses [6]. A variety 
of studies have shown that malaria resistance is enhanced in younger patients. At first it was 
thought that the resistance is innate in that the mechanisms of resistance work in the early stages 
of diseases or infections. This precedes the immune response that adapts in order to take over 
after the course of a few days [4]. However, it is suggested that if malaria protection by HbS in 
HbA/HbS individuals was an innate resistance, it should be independent of age which is not 
consistent with the findings of the study in Sudan [4].  
Chronic intravascular hyper-hemolysis has been found to characterize a new, specific 
type of sickle cell anemia subphenotype. Identification of this may highlight the finding of 
disease modifying factors in order to develop new therapies [7]. This novel subphenotype has 
shown signs of reduced vasoocclusive pain but sooner mortality rates as well as increased 
reticulocytosis which is a physiological response to extravascular and intravascular red blood cell 
destruction [7]. Lactic dehydrogenase (LDH) can be distributed in order to measure hemolysis 
levels and would be a possible identifier of this subphenotype. Association of lower HbF levels 
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has been found in relation to decreased α thalassemia, a genetic factor that has been found to 
reduce anemia and hemolysis [7]. This subphenotype has illustrated increased severity as high 
levels of HbF are associated with reduced pain, acute chest pain, and mortality as HbF has the 
ability to inhibit polyermization of HbS. In turn, this decreased vasoocclusion and hemolysis [7]. 
Another common symptom of sickle disease is hypoxia which is especially common in 
children. This has been associated with increased severity of the disease characterized by low 
levels of HbF resulting in cases of abnormal lung function [8]. This can only partially be 
explained by anemia as one study found that it represented only 5% of arterial oxygen 
desaturation. [8]. One factor that potentially explains the diminished affinity of HbS for oxygen 
is the increased concentration of erythrocyte 2,3-biphosphoglycerate. This decreased the life 
span of an erythrocyte via apoptosis due to increased Ca (2+) activity [9]. 
A major cause of death in patients with sickle cell disease may be pulmonary 
hypertension. Frequent reports of sudden death in adults with sickle cell disease in the absence of 
coronary artery disease has been associated with hemolysis [8]. Despite having lower 
pulmonary-artery pressures and higher cardiac outputs than patients with primary pulmonary 
hypertension, patients with sickle cell disease and pulmonary hypertension had a significantly 
higher mortality rate than did patients with sickle cell disease who did not have pulmonary 
hypertension. [10] Chronic hemolysis releases hemoglobin into plasma which can catalyze the 
reaction between oxygen and nitrogen resulting in acute and chronic pulmonary vasoconstriction 
by increasing the transcriptional up-regulation of adhesive molecules [10].  
 Echocardiography can be used to identify at-risk patients through the noninvasive 
measurement of tricuspid regurgitant jet velocity. This prognostic tool can provide additional 
data alongside the transcranial carotid Doppler flow-velocity assessment, which is used to 
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predict the risk of stroke in children with sickle cell disease. [10] Research has found 
hydroxyurea increases levels of HbF, therefore, decreasing morbidity from vasoocclusive 
complications in patients [11]. A more extreme form of treatment is the transplantation of 
hematopoietic stem cells. Unfortunately, patients with hemoglobin-based diseases, such as sickle 
cell disease, have been found to have transplant rejection more frequently than other blood 
disorders including aplastic anemia, severe combined immune deficiency, and malignant 
conditions [12]. The common downfall results from iron overload leading to liver disease. 
Patients with β-thalassemia who undergo transplantation early have seen a higher success rate 
[12]. 
 It is vital to continue research on not only treatments, but the fundamental aspects of the 
disease. By understanding the biochemical breakdown of sickle cell disease, therapeutic options 
can be enhanced in addition to the potential for a cure. The variations discovered thus far have 
demonstrated the complexity of the disease as well as an opportunity to work from a genetic 
basis to a physiological understanding. Sickle-cell disease still contains many unknowns and 
maintains an unpredictable course; however the benefits of heterozygosity provide justification 
of continued research.  
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Abstract 
Cystic fibrosis is an extensively studied disorder caused by a monogenic inherited 
disease. This disease results from mutation in the cystic fibrosis transmembrane regulator gene. 
CFTR codes for a complex protein that is vital to normal functioning. This research paper 
compiles information over the disorder and examines life with the disease from a clinical, 
molecular, and genetic viewpoint. The method for writing included looking over various 
scientific articles. 
 
Introduction 
   Cystic fibrosis is a fairly common autosomal recessive disorder in European 
populations. It is characterized by thick and sticky fluid in the cells that produce mucus, sweat, 
and digestive juices. Symptoms include pain in the abdomen, burning sensation in the chest, 
coughing, wheezing, and gastrointestinal problems. Patients with CF will have salty-tasting skin, 
frequent lung infections, poor growth and weight gain, frequent greasy, bulky stool or problems 
with bowel movements, and even infertility in males.  The secretions of the cell aren’t thin and 
slippery as in normal people, so instead of acting as a lubricant, the secretions plug up tubes, 
ducts, and passageways. The buildup of mucus traps bacteria, which increases the risk for 
infection. This leads to lung damage and eventually respiratory failure. The mucus buildup 
prevents the release of digestive enzymes from the pancreas, making the break down and  
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absorbance of food difficult. The disorder requires daily attention but those diagnosed with it can 
live fairly normal lives with an average life expectancy in the 20s and 30s.  
     Cystic fibrosis has a prevalence of 1 in 2500 European populations. Cystic fibrosis 
occurs in roughly 1 in 2000 births in northern European population (Zemanick et al. 2010). 
According to the National Institute of Health approximately 30,000 people in the US are living 
with cystic fibrosis. Every year there are 1,000 new cases. The majority of people with CF are 
diagnosed by two years old.  
     It is speculated that cystic fibrosis has been around since 3,000 BC (Busch 1989). 
Although the first paper about CF wasn’t published until 1938. Dorothy Hansine Andersen 
published “Cystic Fibrosis of the Pancreas and its Relation to Celiac Disease: A clinical and 
Pathological Study,” in the American Journal of Disease of Children (Andersen 2009). It is a 
complex disorder and the symptoms and severity of the symptoms vary from case to case.  
 
Genetic Component 
     People with cystic fibrosis have inherited two copies of the defective gene. Each copy 
must come from a parent meaning that both parents must be carriers of at least one copy of the 
gene for their offspring to inherit the disease. Carriers of the disease only have one copy and do 
not show any of the symptoms.  
    In 1989 cystic fibrosis was found to be caused by mutations in a previously unstudied 
gene. The novel cystic fibrosis transmembrane regulator (CFTR) gene was predicted to regulate 
transmembrane conductance, and was subsequently shown to function as a channel that allows 
chloride ions to pass through the cell membrane. A great deal was discovered about aspects of  
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CFTR biology that would inform diverse fields such as protein trafficking and membrane 
transport. According to the Cystic Fibrosis Mutation Database there are currently 1,991 CFTR 
mutations. The most common mutation, F508 is a deletion of three nucleotides. This results in a 
loss of the amino acid phenylalanine (F) at the 508th position on the protein (Griesenbach et al., 
2016). The F508 deletion on chromosome 7 has been found in approximately 70% of gene 
carriers for cystic fibrosis and provides an opportunity to offer detection of carrier state both to 
members of the general populations and to members of families whom cystic fibrosis has been 
diagnosed (Knight et al., 1990). This mutation alone, accounts for two-thirds of the mutations in 
cystic fibrosis worldwide.  
    The different mutations that cause CF can be divided into four classes. This first class of 
mutations affect protein production and include the nonsense mutation G542X. There are 
mutations throughout the CFTR gene that produce premature termination signals because of 
splice site abnormalities, frameshifts due to insertions or deletions, or nonsense mutations (Tsui, 
1992). The second class of mutations affect processing, where proteins fail to progress through 
the biosynthetic pathway. This includes the most common mutation, deletion of phenylalanine at 
residue 508 (F508). The third class is defined by problems in protein regulation. An example of 
this is the G551D mutation. Although missense mutations have been reported in the regulatory 
domain, there appear to be fewer mutations than in other parts of the protein (Welsh and Smith, 
1993). The fourth class of mutations causing CF result from defective conducting, where the rate 
of ion flow through a single open channel is reduced. The missense mutation R117H in the first 
membrane-spanning domain falls into this class.  
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 The product of the CFTR gene is a chloride ion channel important in creating sweat, 
digestive juices, and mucus. When there is a mutation in this gene it prevents normal secretion 
from the chloride ion channels. The absence of this gene function is what cause the thick mucus 
in patients with CF.  
   The CFTR gene was cloned and identified to produce a protein, the CFTR protein that 
regulates chlorine ion channels. This seemed to be the cause of the thickening of mucus. It was 
believed that lack of this gene is what caused the hyper-mucosity. Further research has found that 
the mechanism for this is complex and varies from organ to organ with lungs being the most 
complex. It is now hypothesized that it is actually a gene downstream to this gene that causes the 
symptoms that we see in the people with the disease. The mucus hyper production that typifies 
CF does not appear to be a direct cause of a defective CFTR but, rather, to be a downstream 
consequence. In organs like the lung, up-regulation of mucin gene expression by inflammation 
results from chronic infection; however, in other instances and organs, the inflammation may 
have a non-infectious origin (Kreda, 2016). Since there are many variations of the disease it is 
hard to pinpoint the exact cause and it may not be the same for all mutations.  
 
Molecular Biology and Biochemistry of disease 
  Mutations in the CFTR gene affect multiple organs, including the intestine, sweat glands, 
pancreas and the reproductive system, but cystic fibrosis lung disease causes most morbidity and 
leads to premature mortality in cystic fibrosis patients (Griesenbach et al., 2016). CF mostly 
affects the epithelium cells of the lungs, pancreas, liver, and kidneys. The mutation causes either 
loss of function or dysfunction. The reason that death from lung infection is so predominant is  
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due to the dehydration of liquid on the surface of airways. This prevents ciliary action of the cells 
that normally move mucous away. Another alternative is that the disorder causes inflammation in 
the host. Patients with CF are susceptible to opportunistic bacteria, most notably Pseudomonas 
aeruginosa (Zemanick et al. 2010).  This theory that inflammation is what causes eventual lung 
breakdown is less widely accepted. The role of CFTR expression in inflammatory cells such as 
neutrophils, macrophages, and more recently T cells, has been widely, and so far, inconclusively 
debated, but studies overall appear to suggest a potential defect in adaptive immune responses in 
patients with CF, which may explain the exaggerated pulmonary inflammatory responses that 
have been generally observed, an area that requires further studies (Griesenbach et al., 2015). 
 CFTR is found at the q31.2 locus of chromosome 7 (Zengerling, 1987). It is 230,000 
base pairs long, and encodes for a protein that is 1,480 amino acids long. While there are 
approximately 2,000 different alleles in the CFTR gene associated with the diseases, there is no 
evidence that all these cause the disease phenotype. CF allele distribution varies by population. It 
is hypothesized that having CF benefited from resistance to cholera and other causes of diarrhea. 
That is heterozygous individuals would be less susceptible to cholera. The selection of the CF 
mutation and its cellular consequences present evidence which suggests that resistance to cholera 
may have been the environmental factor which selected CF heterozygotes over their ‘normal’ 
homozygote cohort (Rodman 1991). A study done by Patrick Sosnay at John Hopkins University 
looked at genotype and phenotype data for 39,696 affected people in clinics and registries and 
clinics in North America and Europe. In these individuals, 159 CFTR variants had an allele 
frequency of 0.01%. These variants were evaluated for both clinical severity and functional 
consequence, with 127 (80%) meeting both clinical and functional criteria consistent  
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with disease. Assessment of disease penetrance in 2,188 fathers of individuals with cystic 
fibrosis enabled assignment of 12 of the remaining 32 variants as neutral, whereas the other 20 
variants remained of indeterminate effect (Sosnay et al., 2013). This study is significant because 
it shows that there are a lot of different mutations in the CFTR gene that give rise to CF. Those 
with a single working copy are carriers, but otherwise function normally. The most current 
theory on how cellular defect can cause clinical effects is that defective ion transport leads to 
dehydration in the airway epithelia, and therefore thickening mucus. Population based studies of 
CF are becoming more popular, with 1.2 million people subjects in the US alone. Genetic testing 
is highly recommended for people who are showing symptoms and for couples who might be 
carriers for the gene.  
 
Clinical aspects and organismal phenotype 
  Screening for CF includes testing for immunoreactive trypsinogen, then confirmation 
through a scan for CFTR mutations. Most children are diagnosed by six months of age. Diabetes 
is the most common non-pulmonary complication, but lung disease and infertility are also issues.  
There is a wide variability in the disease and most treatments are tailored to the 
individual. Most treatment options are aimed at reducing symptoms of the disease rather than the 
cause of the disease. There are a variety of different therapies that patients can go through. 
Airway clearance helps to get rid of thick mucus in the lungs. This therapy may require a 
respiratory therapist. An inflatable vest vibrates the chest at high frequencies to help loosen and 
thin mucus. Inhaled medicines can also aid in opening air passageways. A liquid medicine is 
usually made into a mist or aerosol. The medicine is then inhaled via a nebulizer. Pancreatic  
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enzyme supplement capsules can also be taken with every meal to help facilitate the absorption 
of important nutrients. Antibiotics include Piperacillin, Azithromycin, Aztreonam, 
Ciprofloxacin, and Tobramycin. All of these drugs are designed to treat bacterial infections. 
Tobramycin is specially designed to treat lung infections.  
  CF is equally prevalent in males and females, but females have a slightly shorter life 
expectancy. The reason for this is unknown but the gap is decreasing as healthcare becomes 
better and more accessible. Similar “gender gaps” have been seen in asthma and COPD (chronic 
obstructive pulmonary disease). Researchers have speculated that sex hormones play a role in 
this gap. More research needs to be done as there are many factors affecting life span such as 
exercise, nutrition, socioeconomics, and environment.  
People suffering from CF are often given a special diet or a list of recommended foods. 
This diet is high in fat and calories. Since the mucus is so thick in the intestines, it makes it hard 
for nutrients like fats and vitamins to be absorbed. That is why teenagers suffering from this 
disorder are usually short and underweight for their age. This also makes them more susceptible 
to illness as their bodies can’t fight off infections very well. Consuming extra calories aids in 
fighting off infections as well as keeping their lungs strong. Even if the patient isn’t feeling 
hungry it is necessary to keep consuming food to fight off malnutrition. Just like anyone else 
they need a well-balanced diet. It is recommended that they consume 2,900-4,500 calories per 
day. Just like any other factor of the disease, everyone person has their own nutritional needs. 
Patients are able to work with a CF nutritionist to develop a diet plan for weight gain.  
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Issue for affected individuals and treatments 
    There is no cure for CF and it is a chronic illness. It puts a great deal of emotional stress on a 
person as well as their family. People with CF need constant care, expensive medication, and are 
more prone to depression or anxiety. The disorder is lifelong and also shortens the lifespan of the 
patient. Those suffering from CF are more prone to depression only due to the amount of stress 
they are under combined with the decrease in quality of life. Exercise can be beneficial to those 
suffering because it releases endorphins as well as strengthening the lungs capacity. People with 
CF shouldn’t smoke or it will increase their chances of lung disease. Despite requiring daily care, 
CF doesn’t stop people from performing daily tasks such as working or going to school. Patients 
are required to check in with a doctor every three months and the better treatment they receive 
the longer lifespan they will have.  
Treatment includes antibiotics, chest physiotherapy, and pancreatic enzyme replacement 
for those with pancreatic insufficiency. Lung transplants are also an option. Gene therapy has 
been explored as a potential cure for CF. It is focused around trying to put a functional copy of 
the CFTR gene into affected cells. Gene transfer has been attempted multiple times, with 
liposomes and viral vectors in animal models and in clinical trials. Unfortunately these methods 
were inefficient. This is because very few of the cells take up the vector and express the gene. 
Pulmonary gene therapy is especially difficult because the lung is a complex organ designed to 
keep out foreign bacteria and viruses. Some gene therapy may not completely fix CFTR gene 
function but even a little bit can improve lung disease. The discovery that even a slight 
improvement in gene function can improve the disease has renewed interest in gene therapy as a 
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form of treatment. Extensive antimicrobial treatment can be used to eradicate infections in the 
lungs. Unfortunately this gives rise to resistant strains of bacteria. 
  The US food and Drug administration approved the first drug that targeted the cause of 
cystic fibrosis in 2012. This drug, ivacaftor, helps to reopen chloride channels that are closed by 
G551D mutation. According to the FDA website, two 48 week clinical studies were conducted 
with 213 patients. In both studies, patients taking ivacaftor showed significant and sustained 
improvement in lung function. Before 2012 most drugs were only administered to treat 
symptoms of the disorder. The FDA approved the second drug to target the root cause of CF in 
2015. These CFTR modulators are a breakthrough in treatment and have the potential to add 
decades to the lives of CF patients.   
The possibility of a lung transplant can improve the lives of patients. In this surgical 
procedure the unhealthy lung is removed and replaced with a healthy one. A lung transplant 
requires a lot of planning and is fairly expensive. Sometimes a transplant called living donor 
lobar lung transplant is performed where only the lower lobe of the lung is transplanted. The 
major risk of this procedure is rejection of the organ or infection. It is only recommended in 
people who have extensive lung damage. It is important to note that the transplant does not cure 
the problem of CF and the new lung will also be affected by the thickening of the mucus. That is 
why this procedure is less common.  
 
Conclusion 
    In some countries, newborns are screened for this disorder. The knowledge about the disease 
is expanding and many new treatments have finished clinical testing and are being acclimated  
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into mainstream treatment. Our understanding of cystic fibrosis pathophysiology and genetics is 
constantly expanding and being refined, leading to improved management of the disease and 
increased life expectancy in affected individuals (Griesenbach et al., 2016). There is still much 
that is not known about CF such as what other modifier genes affect disease progression. There 
are other challenges like adequate healthcare. Most drugs for CF are expensive and not everyone 
can afford them. Even more important a lot of countries don’t have access to sufficient health 
care. Developing drugs is a long and costly process. While scientists may be close to finding a 
permanent cure, it will be years before the drug is put on the market. Current medicine has 
greatly improved the quality of life for people living with CF. Hopefully patients will see a 
breakthrough in treating the cause of the disease. Either way one thing is for certain, more 
research needs to be done. 
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